CURRICULUM VITAE

Richard Barry Moss, M.D.

PERSONAL INFORMATION

Date of Birth: October 30, 1949

Place of Birth: New York, NY
Citizenship status: United States

Business address: Center of Excellence in Pulmonary Biology
Stanford University Medical Center
770 Welch Road, Suite 350
Palo Alto, CA 94304-5882

Telephone: (650) 725-8188
Telefax: (650) 723-5201
E-mail: rmoss@stanford.edu
Web: http://med.stanford.edu/profiles/Richard_Moss
http://med.stanford.edu/pedpulmonary/Homepage.html
https://www.researchgate.net/profile/Richard_Moss
https://scholar.google.com/citations?user=RfWN0DwAAAAJ&hl=en
https://linkedin.com/in/richard-b-moss-57a4873a/

EDUCATION

Undergraduate: Columbia University
New York, NY
Bachelor of Arts (1971)

Graduate: State University of New York
Downstate Medical Center
New York, NY
Doctor of Medicine (1975)

CLINICAL TRAINING

Internship and Residency: Pediatrics (1975-77)
Children's Memorial Hospital
McGaw Medical Center
Northwestern University
Chicago, IL

Fellowships: Allergy-Immunology (1977-79)
Department of Pediatrics
Stanford University Medical Center

Pediatric Pulmonology (1980-81)
Department of Pediatrics
Stanford University Medical Center

PROFESSIONAL BACKGROUND

1981-1988 Assistant Professor of Pediatrics, Stanford University Medical School

1981- Attending Physician, Lucile Packard Children's Hospital at Stanford

1981-2010	Attending Physician, Stanford University Hospital
1981-1991	Associate Director, Cystic Fibrosis Center Children's Hospital at Stanford Stanford University Medical Center
1982; 1991-1994	Acting Chief, Division of Allergy-Immunology & Respiratory Medicine Department of Pediatrics Stanford University Medical School
1983-2001	Director, Allergy Reference Laboratory Lucile Packard Children's Hospital at Stanford
1985-2005	Director, Ross Mosier Laboratory for Cystic Fibrosis Research Children's Hospital at Stanford/ Lucile Packard Children's Hospital at Stanford
1988-1994	Associate Professor of Pediatrics (Clinical), Stanford University School of Medicine
1989-1995	Co-Director, Allergy-Immunology Fellowship Training Program Stanford University School of Medicine
1991-	Director, Stanford Cystic Fibrosis Center
1994-1995	Chief, Division of Allergy-Immunology, & Respiratory Medicine Department of Pediatrics Stanford University Medical School
1994-2010	Professor of Pediatrics, Stanford University Medical Center
1995-2005	Chief, Division of Pulmonology Department of Pediatrics Stanford University Medical School
2005-2009	Chief, Division of Allergy-Immunology Department of Pediatrics Stanford University Medical School
2005- 2010	Director, Allergy-Immunology Fellowship Training Program Stanford University School of Medicine
2010-	Professor of Pediatrics Emeritus Stanford University

LICENSURE

1976	Illinois, T-7762
1977	California, G35650

BOARD CERTIFICATION

1976	National Board of Medical Examiners
1981	American Board of Pediatrics, certificate #6128
1981	American Board of Allergy and Immunology, certificate #2206

1986	Diagnostic Laboratory Immunology (Conjoint Board of the American Boards of Internal Medicine, Pediatrics, and Allergy-Immunology), certificate #38

HONORS, AWARDS, INVITED LECTURES

1970-1971	Dean's List, Columbia University
1974	Alpha Omega Alpha, National Honor Medical Society
1979	Travel Award, American Academy of Allergy and Immunology
1980-1981	Medical Research and Training Award, California Thoracic Society
1980-1981	American Lung Association Training Fellowship
1982	International Travel Award, National Institute of Allergy and Infectious Disease
1985	International Travel Award, International Association of Allergology and Clinical Immunology
1986	Invited Speaker, International Symposium on Clinical Immunology and the Role of IgG_4, San Francisco, CA
1987	Invited Symposium Speaker, First North American Cystic Fibrosis Conference, Toronto, Canada
1990	Invited Plenary Speaker, 1990 International Cystic Fibrosis Conference and North American Cystic Fibrosis Conference, Washington, DC
1994-1995	Reviewer, Special Emphasis Panel for Tuberculosis Academic Awards, National Heart, Lung, and Blood Institute
1995-1996	Reviewer, Special Emphasis Panel for Asthma Academic Awards, National Heart, Lung, and Blood Institute
1996-1999	Consultant, The United States Pharmacopoeia Convention
1996	Consultant, Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine, National Academy of Sciences
1996	Reviewer, Special Emphasis Panel, Biological and Physiological Sciences, Division of Research Grants, National Institutes of Health
2003-	Reviewer, National Institutes of Health/National Center for Research Resources, General Clinical Research Centers site visit team
2003	Invited Plenary Speaker, North American Cystic Fibrosis Conference, Anaheim CA

2001-	Marquis' *Who's Who in Medicine and Healthcare* Consumers' Research Council of America, *America's Top Pediatricians – Pulmonology* Best Doctors, Inc., *Best Doctors in America*
2003	Cystic Fibrosis Research Inc Professional Excellence Award
2006	Marquis' *Who's Who in America*
2010	NIH-NHBLI Special Emphasis Panel Clinical Trials of Novel Therapy for Lung Diseases
2012	Invited Plenary Speaker, International Society of Human and Animal Mycology, Berlin Germany
2017	Cystic Fibrosis Champion Award Cystic Fibrosis Research, Inc.
2018	William J Martin II Distinguished Achievement Award American Thoracic Society – Public Advisory Roundtable
2022	Paul M Quinton Cystic Fibrosis Research Legacy Award Cystic Fibrosis Research Institute

PROFESSIONAL SOCIETIES
Fellow, American Academy of Allergy, Asthma, and Immunology
Fellow, American Academy of Pediatrics
Fellow, American College of Chest Physicians
Member, American Thoracic Society
Member, Pediatric Academic Society (elected 2005)

GRANTS, CONTRACTS, AND CLINICAL TRIALS
1983-1984 NIH Biomedical Research Support Grant, "Blocking Antibodies to *Pseudomonas aeruginosa* in Cystic Fibrosis" (P.I.)

1983-1985 Miles Pharmaceuticals, Inc., "Multicenter Collaborative Project: *Pseudomonas aeruginosa* Endobronchial Infection in Cystic Fibrosis. A Prospective Double-blind Controlled Study of Two Antimicrobial Regimens," (Co-Investigator)

1984 MAST Immunosystems, Inc., "A Comparison of the MAST Inhalant Profile and the Phadezyme RAST" (P.I.)

1985-1986 Cystic Fibrosis Foundation G104 6-01, "Natural and Human Hybridoma CF Antipseudomonal Antibodies" (P.I.)

1986-1987 Beecham Pharmaceuticals, Inc., "A Multicenter Observer-blind Study of Antibiotic Therapy of *Pseudomonas aeruginosa* Bronchopulmonary Infection in Cystic Fibrosis: Comparison of Three Antimicrobial Drug Regimens," (Co-Investigator)

1986-1987 Glaxo Pharmaceuticals, Inc., "Extended Home Intravenous Therapy in Cystic Fibrosis Patients," (Co-Investigator)

1986-1990 NIH RO1 HL36796, "Late Sequelae of Bronchopulmonary Dysplasia" (Co-P.I. with William Northway)

1987 3M Diagnostic Systems, Inc., "Comparison of Phadezyme RAST to 3M Systems FAST for Specific IgE" (P.I.)

1987-1989 E.R. Squibb & Sons, Inc., "Evaluation of the Immunologic Cross Reactivity of Aztreonam Therapy in Cystic Fibrosis Patients Allergic to Penicillin and/or Cephalosporin Antibiotics" (Stanford P.I.)

1990-1991 Cystic Fibrosis Research, Inc., "Mechanism of β-Lactam Drug Allergy in Cystic Fibrosis" (P.I.)

1991-2009 Cystic Fibrosis Foundation, "Stanford Cystic Fibrosis Care Center" (Center Director)
1991-1992 Stanford Office of Technology Research Incentive Fund, "Evaluation of Maxillary Sinus Treatments in Patients with Antrostomies" (Co-Investigator)

1991-1993 Genentech, Inc.,"A Phase III, Multicenter, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety and Efficacy of Aerosolized Recombinant Human DNase I in Patients with Cystic Fibrosis" (Stanford P.I.)

1992-1993 Genentech, Inc., "A Phase II, Multicenter, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety and Efficacy of Aerosolized Recombinant Human DNase I in Hospitalized Patients with Cystic Fibrosis Experiencing Acute Pulmonary Exacerbations" (Stanford P.I.)

1992-1993 Genentech, Inc., "A Multicenter Open-label Treatment Protocol to Provide Aerosolized rhDNase Therapy to Patients with Cystic Fibrosis" (Stanford P.I.)

1992-1993 Genentech, Inc., "A Multicenter Epidemiologic Protocol to Evaluate Pulmonary Function and the Rate of Respiratory Tract Infections in Patients with Cystic Fibrosis" (Stanford P.I.)

1992-1993 Cystic Fibrosis Foundation, "CFTR Expression in Human T Cell Clones" (Co-Investigator)

1992 Genentech, Inc., "A Randomized Multicenter Study to Evaluate the Safety and Efficacy of Aerosolized Recombinant Human DNase I administered with Three Different Nebulizers in Patients with Cystic Fibrosis"(Stanford P.I.)

1993 Genentech, Inc., "A Multicenter, Double-blind, Placebo-controlled Protocol to Evaluate the Safety and Efficacy of Aerosolized Recombinant human DNase I Therapy in Patients with Cystic Fibrosis Who Have Advanced Lung Disease" (Stanford P.I.)

1993-1994 Cystic Fibrosis Foundation, "CFTR, Chloride Conductance, and Immunocompetence in T Cells" (Co-Investigator)

1993-1994 Genentech, Inc., "Effect of Device Resistance and Dynamic Lung Function on Peak Inspiratory Flow Rates in Chronic Obstructive Lung Diseases" (Co-investigator)

1993-1994 Univax Biologics, Inc., "A Single-blind, Multi-Center, Study to Evaluate the Safety and Pharmacokinetics of a Hyperimmune Immunoglobulin Intravenous Targeted Against Mucoid *Pseudomonas aeruginosa* in Patients with Cystic Fibrosis" (P.I.)

1992-1995 NIH RO1 DK 45910-01, "Ursodeoxycholic Acid Therapy in Patients with Cystic Fibrosis-Associated Liver Disease" (Stanford Co-P.I. with Ricardo Castillo)

1994-1995PathoGenesis, Inc., "A Phase II Clinical Trial to Compare Safety, Efficacy and Pharmacokinetics of an Aminoglycoside (Tobramycin) Formulation Administered by 3 Different Nebulizer Delivery Systems to Patients with Cystic Fibrosis" (Stanford P.I.)

1994-1995 Genentech, Inc., "A Phase IV, Multicenter Study to Monitor the Long-term Safety and Efficacy of Pulmozyme in Cystic Fibrosis Patients Who Participated in a Phase III Trial" (Stanford P.I.)

1994-1995 Smith Kline Beecham, Inc., "A Multicenter, Double-Blind, Placebo-Controllled, Parallel-Group Comparison of the Safety and Efficacy of Oral Twice-Daily Administration of SB205312 with Inhaled Vanceril in Patients with Mild to Moderate Asthma" (Stanford P.I.)

1994-2005 Genentech, Inc., "Epidemiologic Study of Cystic Fibrosis" (Stanford P.I.)

1995-1996 PathoGenesis, Inc., "A Phase III Placebo Controlled Trial to Study the Safety and Efficacy of Tobramycin for Inhalation in Patients with Cystic Fibrosis" (Stanford P.I.)

1995-1996 Univax Biologicals, Inc./North American Biologicals, Inc., "A Randomized, Multi-Center, Double-Blind, Placebo Exopolysaccharide *Pseudomonas aeruginosa* Immune Globulin Intravenous (Human) (MEP IGIV) in Reducing the Frequency of Acute Pulmonary Exacerbation in Patients with Cystic Fibrosis" (Stanford P.I.)

1995-1996 Cystic Fibrosis Foundation, "Assessment of Safety and Efficacy of Nebulizers" (Stanford P.I.)

1995-1996 NCRR General Clinical Research Center M01 RR00070/ Cystic Fibrosis Research, Inc./Targeted Genetics, Inc., "Phase I Evaluation of Adeno-Associated Virus Mediated Gene Transfer of the Cystic Fibrosis Transmembrane Conductance Regulator in the Maxillary Sinus of Patients with Antrostomies" (Co-Investigator)

1996-1997 Cystic Fibrosis Research, Inc., "T Cells in Cystic Fibrosis: Interleukin 10 Deficiency" (P.I.)

1996-1997 Immuno Clinical Research Corp., "A Revised Open-label Study of C1-Inhibitor (Human) Vapor Treated Immuno as a Therapeutic Agent for Acute Attacks of Hereditary Angioedema" (Stanford P.I.)

1996-1997 Medical Graphics, Inc., "Electron Beam Computed Tomography of the Chest in Patients with Cystic Fibrosis" (co-P.I. with Terry Robinson)

1996-1998 PathoGenesis, Inc., "An Open-Label Follow-On Trial of Tobramycin Solution for Inhalation in Patients with CF" (Stanford P.I.)

1996-1998 SciClone Pharmaceuticals, Inc., "A Phase I Trial of CPX in Adult Patients with Mild Cystic Fibrosis" (CPX-CLP-PCO-11/19/96-00) (Stanford P.I.)

1996-1998 NCRR General Clinical Research Center M01 RR00070/ Cystic Fibrosis Research, Inc./Targeted Genetics Inc., "Phase II Evaluation of Adeno-Associated Virus Mediated Gene Transfer of the Cystic Fibrosis Transmembrane Conductance Regulator in the Maxillary Sinus of Patients with Antrostomies" (Co-Investigator)

1996-1998 Cystic Fibrosis Research, Inc., "Electron Beam Computed Tomography, Pulmonary Function, and Exercise Endurance During a Pulmonary Exacerbation in Patients with Cystic Fibrosis" (P.I.)

1996-1998 The DuPont Merck Pharmaceutical Company, "A Phase IIA Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of DMP 777 in Adult Patients 18 Years of Age and Older with Cystic Fibrosis" (Stanford P.I.)

1997-1999 The DuPont Merck Pharmaceutical Company "A Phase IIA Multiple Dose-Escalation Study to Evaluate the Lung-Specific Bioefficacy of Three Different Dose Levels of DMP 777 in Adult Patients 18 Years of Age and Older with Cystic Fibrosis" (Stanford P.I.)

1997-1999Cystic Fibrosis Foundation, "High Resolution CT Imaging in Mild Cystic Fibrosis Pulmonary Disease Using Electron Beam Computed Tomography" (P.I.)

1998-2000 Genentech, Inc., "A Multicenter, International, Randomized, Placebo-controlled, Double-blind Study to Determine the Effect of Pulmozyme® on Pulmonary Function Over 96 Weeks in Subjects with Cystic Fibrosis Aged 6-10 Years" (Stanford P.I.)

1998-2000 Targeted Genetics, Inc., "A Phase I Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis Patients with Mild Lung Disease" (Stanford P.I.)

1997 Genentech, Inc., "Validation of a Disease-specific Quality of Life Questionnaire for Cystic Fibrosis" (Stanford P.I.)

1998-2003 Cystic Fibrosis Foundation, "Aminoglycoside versus Conventional Therapy Combined with Beta-Lactam in Cystic Fibrosis Patients with Pulmonary Exacerbations" (Stanford P.I.)

1999-2000 IntraBiotics Pharmaceuticals, Inc., "A Phase I, Randomized, Placebo-controlled, Double-blind, Multicenter Safety and Tolerability Study of Ascending Multiple Inhaled Doses of IB-367 in Adult Patients with Cystic Fibrosis" (Stanford P.I.)

1999-2001 Cystic Fibrosis Foundation, "Diabetes Therapy to Ameliorate Protein Catabolism in CF" (Stanford P.I.)

1999-2001 Chiron Corp., “A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children with Cystic Fibrosis” (Stanford P.I.)

1999-2001 AstraZeneca, Inc., “Safety and Efficacy Study of Two Dosage Levels of Pulmicort Respules vs Placebo in Infants 6 to 12 Months with Mild-Moderate Asthma” (Stanford P.I.)

1999-2009 Cystic Fibrosis Foundation Therapeutics, Inc., “Therapeutics Development Network Center” Site (P.I.)

2000-2001 Medimmune Inc., “A Phase IV Study of the Safety of Synagis® (Palivizumab) for Prophylaxis of Respiratory Syncytial Virus in Children with Cystic Fibrosis” (Stanford P.I.)

2000-2002 Intermune, Inc., “A Phase I/II Study of Interferon Gamma-1b by Inhalation for the Treatment of Patients with Cystic Fibrosis” *(National P.I.)*

2001-2003 Targeted Genetics, Inc., “A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized tgAAVCF in Cystic Fibrosis Patients with Mild Lung Disease *(National P.I.)*

2001-2002 Cystic Fibrosis Foundation Therapeutics, Inc., “Standardization of the Measurement of the Nasal Membrane Transepithelial-Potential Difference” (Stanford P.I.)

2001-2002 Cystic Fibrosis Foundation Therapeutics, Inc., “Validation of Sputum Induction as Outcome Measure for Lower Airway Sampling in Patients with Cystic Fibrosis” (Stanford P.I.)

2001-2002 Boehringer Ingelheim, “A Randomized, Double-blind Within Dose, Placebo-controlled study to investigate the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients” (Stanford P.I.)

2001-2002 Boehringer Ingelheim, “A randomized, double-blind within dose, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of repeated oral doses (15-day dosing) of BIIL 284 BS in adult and pediatric cystic fibrosis patients” (Stanford P.I.)

2001-2002 Cystic Fibrosis Foundation Therapeutics, Inc., “Standardization of Cystic Fibrosis Sweat Rate Procedure” (Stanford P.I.)

2001-2002 Chiron Corp., “An Open Label Study of Tobramycin for Inhalation in Young Children with Cystic Fibrosis” (Stanford P.I.)

2001-2003 Cystic Fibrosis Foundation Therapeutics, Inc., “Cystic Fibrosis Twin Study” (Stanford P.I.)

2001-2006 NIH-NIDDK, “Diabetes Therapy to Improve Muscle Mass and Clinical Status in CF Subjects with Abnormal Glucose Tolerance” (Stanford P.I.)

2001-2004 Cystic Fibrosis Foundation Therapeutics, Inc., “Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis” (Stanford P.I.)

2002-2003 Altus Biologics, Inc., “A Phase I, Open-Label Safety and Tolerability Study of Oral TheraCLEC-Total in Subjects with Cystic Fibrosis" (Stanford P.I.)

2003-2004 Boehringer Ingelheim, Inc, "A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of 24 weeks of oral treatment with BIIL 284 BS in adult and pediatric cystic fibrosis patients" (Stanford P.I.)

2003-2004 Inspire Pharmaceuticals, Inc., "A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects with Mild to Moderate Cystic Fibrosis Lung Disease" (Co-investigator)

2003-2004 Chiron, “A Phase I Single-dose, Dose-escalation Trial Comparing Safety, Pharmokinetics and Delivery Time of Tobramycin Dry Powder for Inhalation Administered by Nektar T-326 Dry Powder Inhaler Device to Tobramycin Solution for Inhlalation Administered by a Pari LC Plus Jet Nebulizer/DeVilbiss PulmoAide Compressor in Cystic Fibrosis Patients” (Co-investigator)

2003-2004 Corus Pharma, “A Blinded, Multicenter, Randomized, Placebo-Controlled Trial with Aztreonam for Inhalation in Cystic Fibrosis Patients with Lung Disease Due to P. aeruginosa Infection” (Co-investigator)

2003-2004 Altus Biologicals, Inc., “A Phase 2, Active Run-in Randomized, Double Blind Dose Ranging Study of Oral TheraCLEC-Total in Cystic Fibrosis Subjects with Exocrine Pancreatic Insufficiency” (P.I.)

2003-2005 Thrasher Foundation, “Improving Health Care Outcomes of Children and Adolescents with Chronic Disease” (Co-PI with David Bergman MD)

2003-2005 Targeted Genetics, Inc., “A Multicenter, Double-blind, Placebo-Controlled Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis” *(National P.I.)*

2003-2006 Cystic Fibrosis Foundation, “A Study of the Effects of Glutathione and N-Acetylcysteine on Lung Inflammation in Cystic Fibrosis Patients” (Co-investigator)

2004-2006 Genentech, Inc, “A Phase II Randomized Double-blind Parallel-Group Placebo-Controlled Oral Food Challenge Trial of Xolair® (Omalizumab) in Peanut Allergy” (Stanford P.I.)

2004-2006 Cystic Fibrosis Foundation Therapeutics, Inc., “Assessment of Induced Sputum as a Tool to Evaluate Anti-inflammatory Agents in Patients with Cystic Fibrosis” (Stanford P.I.)

2005-2006 Corus Pharma, “A Phase 3, Double-blind, Multicenter, Randomized, Placebo-controlled Trial with Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary P. aeruginosa Requiring Frequent Antibiotics” (Stanford P.I.))

2005-2006 Corus Pharma, “A Phase 3 Follow-on Study of Multiple Courses of Aztreonam Lysinate for Inhalation for Cystic Fibrosis Patients Needing Anti-pseudomonal Antibiotics” (Stanford P.I.)

2005-2006 Inspire Pharmaceuticals, Inc., "A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease" (Stanford P.I.)

2005-2007 Dyax, Inc “An Ascending Four Dose Placebo Controlled Study to Assess the Efficacy and Tolerability of DX-88 (Recombinant Plasma Kallikrein Inhibitor) Adminstered Following Onset of Acute Attacks of Hereditary Angioedema (Stanford P.I.)

2005-2007 Oxnard Foundation, “A Phase I/II Single Center Blinded Randomized Controlled Study of Xolair in Subjects with Moderate to Severe Atopic Dermatitis with Food Allergy” (P.I.)

2005-2007 Genentech, Inc, “ An Epidemiologic Study of Xolair® (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma” (Stanford P.I.)

2005-2010 Cystic Fibrosis Foundation Therapeutics, Inc., “Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas aeruginosa Airway Infection in Young Patients with Cystic Fibrosis” (Stanford P.I.)

2006-2009 Inspire Pharmaceuticals Inc, “A Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Efficacy and Safety Study of Denuofosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease” (Stanford P.I.)

2006- 2007 Eurand, “An Open-Label Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product Microtabs in Pediatric Patients with Cystic Fibrosis and Exocrine Pancreatic Insufficiency” (Stanford P.I.)

2006-2008 PTC Therapeutics, “A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense Mutation Mediated Cystic Fibrosis” (Stanford P.I.)

2006-2007 Dyax, Inc and Genzyme, “EDEMA3: A Double-Blind, Placebo Controlled Study Followed by a Repeat Dosing Phase to Assess the Efficacy and Safety of DX-88 for the Treatment of Acute Attacks of Herediatry Angioedema” (Stanford P.I.)

2006- 2008 Mpex Pharmaceuticals, Inc., “A Phase 1, Single- and Multi-dose, Single-blind, Placebo-control, Randomized Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of MP-376 Solution for Inhalation at up to Three Dose Levels Delivered by the Pari eFlow® Electronic Nebulizer for 14 days to Stable Cystic Fibrosis Patients” (Stanford P.I.)

2007-2008 GlaxoSmithKline, “An open label, dose-ascending, single- dose study to investigate the pharmacokinetics of SB-656933 in subjects with cystic fibrosis” (National P.I.)

2007-2008 Altus Biologicals, Inc. “A Phase III, Randomized, Double-Blind, Placebo-Controlled ClinicalStudy Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency” (Stanford P.I.)

2007-2009 Vertex Pharmaceuticals, Inc., “A Phase 2a, Randomized, Double-Blind, Placebo Controlled Study of VX 770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects with Genotype G551D" (Stanford P.I.)

2007-2008 Stanford Center for Clinical and Translational Education and Research, “Addressing a Critical Bottleneck in Cystic Fibrosis Trials: An Integrative Tool for Small Metabolite-Based Outcomes” (P.I.)

2008-2010 Inspire Pharmaceuticals Inc, “A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease” (Stanford P.I.)

2009-2010 Gilead, “A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis and *Pseudomonas aeruginosa”* (Stanford P.I)

2009-2010 Vertex Pharmaceuticals, “A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX 809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the DeltaF508-*CFTR* Gene Mutation” (Stanford P.I.)

2010- 2011 Inspire, "Open-label Extension of Study 08-110 -- A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease" (Stanfor P.I.)

2006-2011 Novartis, “Natural History of Progressive CF Lung Disease Utilizing Controlled Volumetric Lung CT Imaging, Pulmonary Function Measurements, Sputum Indices, and Clinical Scores in Children with Mild to Moderate CF Lung Disease (Co-Investigator)

2007-2010 Cystic Fibrosis Foundation Therapeutics, Inc., “PharmaNAC: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients” (Co-investigator)

2007-2010 Cystic Fibrosis Foundation Therapeutics, Inc., “Cell-based multifactorial analysis of CF pulmonary exacerbations” (Co-investigator)

2008-2011 Cystic Fibrosis Foundation Therapeutics, Inc., “Electronic Data Capture for NPD Studies” (Stanford P.I.)

2009-2011 GlaxoSmithKline, “A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Treatment Effects and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis (International P.I.)

2010-2011 Vertex Pharmaceuticals, "A Phase 2, Open-Label, Randomized, Multiple Dose Study to Evaluate Safety, Pharmacokinetics, andPharmacodynamic of VX-809 and VX-770 in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation" (Stanford P.I.)

2009-2011 PTC Therapeutics, “A Phase 3 Efficacy and Safety of PTC124 as an Oral Treatment for Nonsense Mutation Mediated Cystic Fibrosis” (Stanford P.I.)

2009-2011 Vertex Pharmaceuticals, “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects with Cystic Fibrosis and the G551D Mutation” (Stanford P.I.)

2001-2015 NIH-NHLBI, “Genetic Modifiers in Cystic Fibrosis Lung Disease” (Co-investigator)

2005-2010 Cystic Fibrosis Foundation Therapeutics, Inc., “Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas aeruginosa Acquisition in Children with Cystic Fibrosis” (Stanford P.I.)

2008-2012 Cystic Fibrosis Foundation Therapeutics, Inc., “Translational Therapeutics Development Center” (Co investigator)

2011-2012 PTC Therapeutics, “A Phase 3 Efficacy and Safety of PTC124 as an Oral Treatment for Nonsense Mutation Mediated Cystic Fibrosis, Extension Study” (Stanford P.I.)

2011-2013 Vertex Pharmaceuticals, "A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX-809 Alone and in Combination with VX-770 in Subjects with Cystic Fibrosis, Homozygous or Heterozygous for the *F508del*-CFTR Mutation" (Stanford P.I.)

2011-2012 CFRI, "CF-ABPA, An Increasing Threat for CF Patients: Clinically Relevant Tools for Diagnosis and Monitoring" (P.I.)

2012-2014 Genentech, Inc., "Complex Biological Mechanisms in Chronic Bronchopulmonary Aspergillosis" (P.I.)

2012-2014 Vertex Pharmaceuticals, "A Phase 3, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis who Have the *R117H-CFTR* Mutation" (International P.I.)

2013-2014 Vertex Pharmaceuticals, "A Phase 3, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation" (Stanford P.I.)

2013-2014 Nivalis Pharmaceuticals, "A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation" (Stanford P.I.)

2014-2016 PTC Corporation, "A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutations Cystic Fibrosis " (Stanford P.I.)

2014- Vertex Pharmaceuticals, "A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation" (Stanford P.I.)

2014- Vertex Pharmaceuticals, "A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation" (Stanford P.I.)

2015-2017 Vertex Pharmaceuticals, **"**Does Ivacaftor Increase WT CFTR Function? In vivo Readout Using Optical Monitoring of Multiple, Identified Single Sweat Glands.**"** (Co-P.I)

2015-2017 Nivalis Therapeutics, "A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients with Cystic Fibrosis Homozygous for the *F508del-CFTR* Mutation" (Stanford P.I.)

2015-2017 ProQR Therapeutics, "A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects with Homozygous DF508 Cystic Fibrosis" (Stanford P.I.)

2015-2017 Vertex Pharmaceuticals, "A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Lumacaftor in Combination with Ivacaftor in Subjects 6 Through 11 Years of Age with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation" (Stanford co-I.)

2015-2017 Vertex Pharmaceuticals, "A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with VX-661 in Combination with Invacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation" (Stanford co-I.)

2015-2017 Vertex Pharmaceuticals, “A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation” (Stanford co-I.)

2016-2017 PTC Corporation, “A Phase 3 Extension Study of Ataluren (PTC124) in Patients with Nonsense Mutations Cystic Fibrosis“ (Stanford P.I.)

2016-2017 Nivalis Therapeutics Inc, “A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of N9115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation and Being Treated with lumacaftor/ivacaftor” (Stanford P.I.)

2015-2018 Celtaxys, Inc. “A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis” (Stanford P.I.)

STANFORD UNIVERSITY MEDICAL CENTER COMMITTEES AND SERVICE

Chair, Pharmacy and Therapeutics Committee Children's Hospital at Stanford	1982-1991
Evaluation and Planning Committee, Department of Pediatrics Stanford University School of Medicine	1982-1983
Committee on Research, Department of Pediatrics Stanford University School of Medicine	1984-1985
Chair, Pharmacy Task Force Academic Program Committee Lucile Salter Packard Children's Hospital	1985-1986
Quality Assurance Committee Children's Hospital at Stanford	1985-1991
Respiratory Therapy Task Force, Academic Program Committee Lucile Salter Packard Children's Hospital	1985-1986
Committee on the Pediatric Residency, Department of Pediatrics Stanford University School of Medicine	1986-1987
Chair, Task Force on Postoperative Care Children's Hospital at Stanford	1988
Search Committee, Chief Operating Officer Lucile Salter Packard Children's Hospital	1989
Quality Improvement Committee Lucile Salter Packard Children's Hospital	1991-1993
Nutrition and Total Parenteral Nutrition Committee Lucile Salter Packard Children's Hospital	1991-1998

Infection Control Committee
Lucile Salter Packard Children's Hospital 1992-2001

Home Health Care Committee
Lucile Salter Packard Children's Hospital 1992-1997

Physician Hospital Organization
Utilization Management/Quality Assurance Committee
Lucile Salter Packard Children's Hospital 1994-1996

Dean's Task Force on Gene Therapy
Stanford University School of Medicine 1994

Genetics Chief Search Committee
Department of Pediatrics
Stanford University School of Medicine 1994

Chair, Pulmonary Division Chief Search Committee
Department of Pediatrics
Stanford University School of Medicine 1995-1996

Documentation & Compliance Committee
Lucile Salter Packard Children's Hospital 1998-2002

Ambulatory Services & Space Task Force
Lucile Salter Packard Children's Hospital 1998-2000

Asthma, Pulmonary and TB Planning Group
Children's Health Initiative
UCSF Stanford Health Care 1999

GCRC Oversight & Review Committee
NIH-NCCR General Clinical Research Center
Stanford University Medical Center 1999-2010

Clinical Operations & Budget Committee
Lucile Packard Children’s Hospital 2000-2010

Faculty Practice Organization Management Committee 2004-2010
Lucile Packard Children’s Hospital

FPO Ambulatory Center Quality Improvement Committee 2004-2010
Lucile Packard Children’s Hospital

Co-Director, Children's Health Research Program 2006-2009
Stanford University Medical Center

Member, Pediatrics Mentoring Program
Spectrum Child Health, Stanford University 2007-2017

Lecturer, Bioscience 109B, Genetic Diversity and
Personalized Medicine
Stanford University School of Medicine 2008

Chair, Search Committee
University Tenure Line Faculty, Pulmonary Biology 2008-2012

Executive Committee
Stanford Center for Clinical and Translational
Education and Research - Spectrum Child Health 2008-2017

Member, Scientific Review Panel
Spectrum Child Health, Stanford University 2008-2017

Quality of Care Review Committee
Pulmonary and Critical Care Medicine
Lucile Packard Children's Hospital at Stanford 2009-2014

Stanford University
Administrative Panel on Human Subjects in Medical
Research (IRB) 2010-2017

Member, Scientific Oversight Committee
Pediatric Pulmonary Fellowship Program
Stanford University 2016-

EXTRAMURAL PROFESSIONAL COMMITTEES & ACTIVITIES

Ad Hoc Grant Reviewer
March of Dimes 1985

External Advisory Board
NIH Cystic Fibrosis Research Center
Case Western Reserve Medical School 1985-1991

Ad Hoc Grant Reviewer
Canadian Cystic Fibrosis Foundation 1986, 1997, 2006-

Clinical Research Grant Review Committee
Cystic Fibrosis Foundation 1987-

Section Abstract Reviewer
North American Cystic Fibrosis Conference 1988-1992, 1995-1998, 2004

Site Visit Review Board
Cystic Fibrosis Foundation 1988

Chair, GAP Conference on Infection, Immunity
and Inflammation
Cystic Fibrosis Foundation 1988

Scientific Advisory Panel on Allergy and Immunology
California Medical Association 1990-1995

Ad Hoc Grant Reviewer
Cystic Fibrosis Research, Inc. 1991-
Immunotherapy Advisory Board

Cystic Fibrosis Foundation & Univax Biologicals, Inc.	1992-1994
Chair, Data Safety Monitoring Committee National Multicenter Controlled Pentoxifylline Trial in Patients with CF Hoechst-Roussel, Inc.	1993-1995
Special Emphasis Panel on Asthma Academic Awards National Heart, Blood and Lung Institute	1994-1995
Special Emphasis Panel on Tuberculosis Academic Awards National Heart, Blood and Lung Institute	1994-1995
Data Safety Monitoring Committee Multicenter Controlled Exosurf Trial in Patients with CF Burroughs-Wellcome, Inc.	1995
North American Conference Planning Committee Cystic Fibrosis Foundation	1995-1998, 2004
Clinical Practice Guidelines Committee Cystic Fibrosis Foundation	1995-1996
Merrem® Advisory Board Zeneca Pharmaceuticals, Inc.	1995-1996
Ad Hoc Grant Reviewer National Science Foundation of Switzerland	1995, 1999
Committee to Study Priorities for Vaccine Development Institute of Medicine National Academy of Sciences	1996
Ad Hoc Grant Reviewer Cystic Fibrosis Association of Germany	1996-
Ad Hoc Grant Reviewer Canadian Cystic Fibrosis Foundation	1997-
Steering Committee CFF Therapeutics Development Center Network	1999-2009
The Chest Foundation American College of Chest Physicians Clinical Research Trainee Awards Committee	2001-2010
California Medical Association Advisory Board for Chest Diseases	2001-2006
Chair, Protocol Review Committee CFF Therapeutics Development Network	2002-2005

GCRC Site Review Committee
NIH-National Center for Research Resources 2002

Speaker, Respiratory and Allergic Disease Foundation 2006-

Ad Hoc Reviewer, Italian CF Foundation 2007-

Ad Hoc Reviewer, Irish CF Foundation 2005-

American Academy of Allergy Asthma and Immunology
Task Force on Fungal Diseases of the Lower Airway 2009-2010

Cystic Fibrosis Foundation
National Resource Center Review Committee 2010

NIH-NHBLI Special Emphasis Panel
Clinical Trials of Novel Therapy for Lung Diseases 2010

American Academy of Allergy, Asthma and Immunology
Task Force on Fungal Diseases of the Lower Airway 2010-11

International Society for Human and Animal Mycology
Working Group on Allergic Bronchopulmonary
Aspergillosis in Asthma 2012-13

External Advisory Committee, University of Pittsburgh 2012
Cystic Fibrosis Research Program, NIH P30/CFF RDP

Cystic Fibrosis Foundation
Translational Advisory Group 2012-17

Ad hoc Reviewer 2013-
German Ministry of Education and Research

Ad hoc Reviewer 2013-
Health Research Board, Ireland

Cystic Fibrosis Foundation
Clinical Research Advisory Board 2017-

JOURNAL EDITORIAL OFFICE
Associate Editor, *Medical Mycology* 2006-2009

JOURNAL MANUSCRIPT REVIEWER
Advances in Genomics and Genetics
American Journal of Asthma and Allergy for Pediatricians
American Journal of Clinical Nutrition
American Journal of Respiratory and Critical Care Medicine
American Journal of Respiratory Cell and Molecular Biology
Annals of Allergy
Asthma Research and Practice
BMJ Case Reports
BMJ Quality and Safety

Chest
Clinical and Diagnostic Laboratory Immunology
Clinical and Experimental Allergy
Clinical Journal of Sports Medicine
Clinical Immunotherapeutics
Clinical Reviews in Allergy
Ebio Medicine
European Respiratory Journal
Expert Opinion on Investigational Drugs
Expert Reviews Ltd
Expert Review of Anti-Infective Therapy
Frontiers in Pediatrics, section Pediatric Pulmonology
Frontiers in Pharmacology
Future Medicine
Future Microbiology
Immunobiology
Infection and Immunity
International Archives of Allergy and Applied Immunology
International Journal of Biochemistry and Cell Biology
Human Gene Therapy
Journal of Adolescent Health
Journal of Allergy and Clinical Immunology
Journal of Allergy and Clinical Immunology in Practice
Journal of Asthma
Journal of Clinical Investigation
JCI Insight
Journal of Clinical Microbiology
Journal of Cystic Fibrosis
Journal of Infectious Diseases
Journal of Infection and Public Health
Journal of Invasive Fungal Infection
Journal of Pediatrics
Journal of Thoracic Disease
The Lancet
Medical Mycology
Mycopathologica
Mycoses
Nature Communications
Pediatric Allergy and Asthma
Pediatric Allergy, Immunology, and Pulmonology
Pediatric Drugs
Pediatric Infectious Disease Journal
Pediatric Pulmonology
Pediatric Research
Pediatrics
PLoS ONE
Postgraduate Medicine
Proceedings of the National Academy of Sciences USA
Respiratory Medicine Case Reports
Respiratory Research
Thorax
UpToDate

SYMPOSIA, CONFERENCES, AND SESSIONS ORGANIZED

Symposium on Rhinitis: Differentiation and Management in Primary Care Practice, Napa, CA, January 27-28, 1984. Co-sponsored by American Academy of Allergy & Immunology and American Academy of Family Practice. Chair.

GAP Conference on Infection, Immunity and Inflammation in Cystic Fibrosis, Williamsburg, VA, June 6-9, 1988. Sponsored by Cystic Fibrosis Foundation. Co-Chair.

Session on Intravenous Immunoglobulin, Protease Inhibitors and Other New Therapies, Fifth Annual North American Cystic Fibrosis Conference, Dallas, TX, October 2-5, 1991. Sponsored by Cystic Fibrosis Foundation. Co-Chair.

Workshop on Clinical Anti-Inflammatory Interventions, Tenth Annual North American Cystic Fibrosis Conference, Orlando, FL, October 24-27, 1996. Co-Chair.

Northern California Cystic Fibrosis Center Physicians and Coordinators Meeting, Napa CA, May 30, 1998. Chair.

Advances in Inhaled Antibiotic Therapy, San Francisco CA, October 9, 1998. Chair.

Lung Disease in Immunoglobulin Deficiency Syndromes. Sunrise Seminar, American Thoracic Society, San Diego CA, April 26, 1999. Co-chair.

Consensus Conference on Allergic Bronchopulmonary Aspergillosis. Cystic Fibrosis Foundation, Bethesda MD, June 12-13, 2001. Co-Chair.

Symposium on Non-CF Bronchiectasis and ABPA, North American CF Conference, Orlando FL, October 27, 2001. Co-Chair with Jim Yankaskas.

Symposium on Asthma and ABPA, North American CF Conference, Orlando FL, October 4, 2002. Chair.

Cystic Fibrosis Foundation Williamsburg Conference, Inflammation Session, Williamsburg VA, June 2, 2003. Co-Chair.

Advances Against Aspergillosis International Conference, San Francisco CA, Sept 9-11, 2004. Organizing Committee and Session Chair.

Workshop on New Approaches to Prevent CF Pulmonary Decline, North American CF Conference, October 2006. Co-Chair.

2nd Advances Against Aspergillosis International Conference, Athens Greece, February 22-25, 2006. Organizing Committee and Session Chair.

3rd Advances Against Aspergillosis International Conference, Miami FL, Jan 2008. Organizing Committee.

Allergic Disease in CF – Manifestations and Management. North American CF Conference, October 17, 2009, Symposium Chair.

4th Advances Against Aspergillosis International Conference, Rome Italy, February 3-6, 2010, Organizing and Scientific Committee. Session Co-Chair. Speaker.

5th Advances Against Aspergillosis International Conference, Istanbul Turkey, January 26-28, 2012. Scientific Committee. Session Moderator. Speaker.

6th Advances Against Aspergillosis International Conference, Madrid Spain, February 27-March 1, 2014. Scientific Committee. Speaker.

7th Advances Against Aspergillosis International Conference, Manchester UK, March 3-5, 2016. Scientific Committee. Speaker.

Symposium, Beyond ABPA: Fungal Disease in CF. Co-chair with Stuart Elborn, North American CF Conference, Indianopolis IN, Nov 2, 2017.

8th Advances Against Aspergillosis International Conference, Lisbon Portugal, January 31-February 3, 2018. Scientific Committee. Session Co-Chair. Speaker.

9th Advances Against Aspergillosis International Conference, Lugano Switzerland February 27-29, 2020. Scientific Committee. Session Co-Chair. Speaker.

INVITED PRESENTATIONS (**selections from 2000-present**)

Children's National Medical Center, Washington DC, January 19, 2000. CF - New Insights and Therapies. Pediatric Grand Rounds.

American College of Chest Physicians/American Academy of Pediatrics, San Diego CA, April 1-4, 2000. A Celebration of Pediatric Pulmonology. Controversies in Sinusitis. The Vulnerable Infant – Bronchopulmonary Dysplasia.

American Thoracic Society/International Lung Conference, Toronto CA, May 6-9, 2000. New Perspectives in Aerosolized Antibiotics. Pediatric Clinical Chest Rounds, Case Discussant.

Johns Hopkins Medical Center. September 7, 2000. Allergic Bronchopulmonary Aspergillosis. Pulmonary Medicine Research Conference.

National Institutes of Health DNA Advisory Committee. September 26, 2000. Phase II Aerosolized Gene Therapy Protocol for Cystic Fibrosis. Public Hearing.

St Louis Cardinal Glennon Children's Hospital/St. Louis University. May 30, 2001. Fungal Complications of Cystic Fibrosis. Grand Rounds. Cytokines in cystic fibrosis. Allergy-Immunology Research Seminar.

Current Concepts in Pediatric Respiratory Disease: San Diego 2001. Children's Hospital San Diego. June 29-30, 2001. Bronchopulmonary Dysplasia: Does it Still Occur and How Should it be Managed?; Cystic Fibrosis: What we've Learned from the Infants and Should we Screen?

South American Congress of Pediatric Pulmonology. Florianopolis Brazil, October 1-5, 2001. Aerosolized Antibiotics.

Community Hospital of Los Gatos Grand Rounds. March 28, 2002. Cystic fibrosis.

Santa Clara Valley Medical Center Pediatric Grand Rounds. May 1, 2002. Cystic Fibrosis.

Respiratory Symposium. Central California Children's Hospital, Madera CA. September 26, 2002. Pathophysiology of Cystic Fibrosis.

North American CF Conference, October 4, 2002. CFF Consensus Conference Recommendations on Diagnosis and Treatment of ABPA.

3rd Anuual Irish Cystic Fibrosis Trust Meeting, Killarney, Ireland, February 8, 2003. Allergic Bronchopulmonary Aspergillosis.

Miami Children's Hospital 38th Annual Pediatric Postgraduate Course, January 27, 2003. Aerosolized Antibiotics in Treatment of Respiratory Infection in Children.

New York Cystic Fibrosis Consortium's Dinner Lecture, March 6, 2003. Treatment Emergent Pathogens: Aspergillus and S. Maltophilia.

UCSF Pulmonary Grand Rounds, San Francisco CA, May 6, 2003. Allergic Bronchopulmonary Aspergillosis.

American Society of Gene Therapy, Workshop on Respiratory Tract: Planning and Executing a Gene Therapy Trial for the Respiratory Tract, Washington DC, June 5, 2003. Aersol Grene Transfer in Cystic Fibrosis: The tgAAVCF Experience.

Postgraduate Institute for Medicine, Update on the Microbiology of Cystic Fibrosis (national teleconference), June 16-18, 2003. Treatment of Emerging Opportunists: Aspergillus.

CFRI Annual Conference, Redwood City CA, July 27, 2003. Gene Therapy Research: How Close are We?

Brazilian Cystic Fibrosis Assocation, Rio de Janeiro, Brazil, September 7-9, 2003. Gene Therapy; Inhalation Antiotics.

Cystic Fibrosis Foundation, North American CF Conference, October 19, 2003. ***Plenary Speaker*****,** Progression of Cystic Fibrosis: Can We Gain the Upper Hand?

Lovelace Respiratory Research Institute, Santa Fe NM, October 14, 2003. New Pharmaceuticals: Inhalational Antibiotics for Airways Infection.

Spanish National Cystic Fibrosis Association, Oviedo, Spain, November 21-22, 2003. Clinical Research in Cystic Fibrosis; Inhalational Antibiotics.

Webcast (sponsored by Chiron and Dannemiller Memorial Education Foundation, June 9, 2004. Rationale and Evidence for Early Antibiotic Treatment of Cystic Fibrosis,

Advances Against Aspergillosis International Conference, San Francisco CA, Sept 9-11, 2004. Session Co-Chair, Immunity and Alergy to Aspergillus. Pathophysiology and Immunology of Allergic Aspergillosis.

Webcast (sponsored by Cystic Fibrosis Foundation), Sept 21, 2004. Going for the Gold in CF Care.

Cystic Fibrosis Gene Therapy (sponsored by Cystic Fibrosis Foundation), Sept 29-30, 2004. Status of AAV Clinical Trials.
Universidade Federal do Rio de Janeiro, Centro de Ciencas da Saude, Instituto de Biofisica Carlos Chagas Filho,

November 26, 2004. Current Status of Inhalational Gene Transfer as a Treatment for Cystic Fibrosis.
Centro de Estudos Olinto de Oliveira, Instituto Fernandes Figueira, Rio de Janeiro, November 26, 2004. Center-Based Care for Cystic Fibrosis: Organization, Elements and Outcome.

Current Status of Early Treatment for CF Lung Infection. Sponsored by Chiron. Lectures at:

- Montreal Children's Hospital-McGill University, Montreal Canada, February 1, 2005
- Children's Hospital-Dahousie University, Halifax Canada, February 2, 2005
- The Ottowa Hospital, Ottowa Canada, February 3, 2005
- Hospital for Sick Children, Toronto Canada, February 4, 2005

Cystic Fibrosis Quality Care for Quality Outcomes. Sponsored by Curatio CME Institute and Helix Medication Communications LLC. Lectures at:
- Children's Hospital, Columbus, February 5, 2005
- Children's Mercy Hospital, Kansas City MO, February 24, 2005
- Lackland Air Force Base, San Antonio TX, May 6, 2005
- Batchelor Children's Institute, University of Miami, Miami FL, July 14, 2005

Cystic Fibrosis. Spotlight Presentation, Independent Citizens' Oversight Committee, California Institute for Regenerative Medicine, Stanford CA, March 1, 2005
A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis, European Cystic Fibrosis Society, Annual Meeting, Hersonissos, Crete, Greece, June 23, 2005

Asthma New Ideas and Treatments. 13th Annual Pediatric Update. Lucile Packard Children's Hospital at Stanford, July 9, 2005

CF Lung Disease: Is There a Threshold for Intervention? Sponsored by MedPro Communications, Inc. Lectures at:
- University of Wisconson, Madison WI, Nov 10, 2005
- West Palm Beach FL, Jan 18, 2006
- Combined Medicine-Pediatrics Grand Rounds, University of Mississippi, Jackson MI, July 11, 2006
- Columbia University Presbyterian Babies Hospital, New York NY, Nov 30, 2006
- Baylor University Texas Children's Hospital, Houston TX, Dec 13, 2006

Winning the Struggle Against CF: What are the Tools? What are the Measures? California Thoracic Society, 2006 Annual Clinical Conference, Carmel CA February 4, 2006

Crtique of Trials in ABPA and Fungal Allergy. 2nd Advances Against Aspergillosis, Athens Greece, Feburary 23, 2006

Update on Cystic Fibrosis Clinical Research. American Thoracic Society American Thoracic Society 2006 International Conference, San Diego CA, May 21, 2006

Asthma, Recent Ideas and Treatment Advances. State University of New York Upstate Medical Center, Pediatric Grand Rounds, Syracuse NY, June20, 2006.

Inhaled Antibiotics for Airway Infection, Jilu Hospital, Shandong University, Jinan, China, Aug 26, 2006.
Practical Asthma – Achieving Success in a Variable Disease (with Gary Rachelefsky MD), Palo Alto CA, Dec 6, 2006.

Fungal Infection in Cystic Fibrosis. Physician's Grand Rounds Discussant, North American Cystic Fibrosis Conference, Anaheim CA, Oct 4, 2007.

Master Clinicians Present Optimizing Care Across a Lifetime: A Cystic Fibrosis TownMeeting™. Postgraduate Institute of Medicine CME Faculty. Six Webcasts, October 2007 – February 2008.

The New Horizon of Cystic Fibrosis in the Emerging Adult Population: An Interactive CME Experience. Medical Education Resources, Inc CME Chair and Faulty. Presentations in New York NY and Los Angeles CA October 2007 and two Webcasts October - December 2007.

Treatment of Early Pseudomonoas aeruginosa Infection – When and How. Dannemiller Memorial Educational Foundation CME Faculty.
- Albany NY, Nov 1, 2007
- Salt Lake City UT, Nov 8, 2007
- Los Angeles CA, Nov 9, 2007

Asthma Mini-Seminar. Popular Pediatric Clinical Topics – 2007. Lucile Packard Children's Hospital CME Course,Mauna Lani Bay HI, Nov 28-30, 2007.

Lymphocytes in Cystic Fibrosis. Workshop on Targeting Inflammation in Cystic Fibrosis. Novartis Institute for Biomedical Research, Horsham UK. March 2008.

Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. Mountain West CF Consortium. Denver CO, April 18-19, 2008.

Glutathione and N-acetylcysteine in Cystic Fibrosis. Mountain West CF Consortium. Denver CO, April 18-19, 2008.

Improving Practices to Preserve Pulmonary Function, A Focus on Pseudomonas aeruginosa.
- Fresno CA, May 23, 2008
- Hollywood CA, June 26, 2008
- Anaheim CA, July 31, 2008
- Sacramento CA, August 15, 2008
- Green Bay WI, September 3, 2008
- Milwaukee WI, September 4, 2008
- Boston MA, September 17, 2008
- Children's Hospital, Philadelphia PA, September 18, 2008
- Columbia Regional Hospital, Columbia MO, July 22, 2009
- St. Louis MO, July 22, 2009
- Webinar (University of Wisconsin), November 11, 2009
- Webinar (Loyola University), December 2, 2009
- Baltimore MD, October 21, 2010

Cystic Fibrosis: Are Clinical Signs and Symptoms a Starting Point or a Midpoint in Lung Disease?
- Burlingame CA, September 10, 2008
- Webcasts, October 1, October 8, 2008
- Pasadena CA, November 6, 2008
- New York NY, November 13, 2008
- Houston TX, December 4, 2008
- Santa Ana CA, January 14, 2009
- Fort Worth TX, February 20, 2009

Cystic Fibrosis – Adult Issues. Department of Medicine, UCSF – Fresno campus, Fresno CA, November 20, 2008

Pediatric Fungal Lung Disease. Grand Rounds, Children's Hospital of Central California, Madera CA, November 20, 2008

Lymphocytes in Cystic Fibrosis: Actors or Voyeurs? Physiology Grand Round, Johns Hopkins School of Medicine, Baltimore MD, December 12, 2008

Childhood asthma. East Bay Asthma Coalition Educational Forum. Oakland CA, April 2009.

Preserving Lung Function in Cystic Fibrosis; Allergic Bronchopulmonary Aspergillosis in Cystic Fibosis. Canadian CF Center lectures:
- University of Calgary, May 6, 2009
- Montreal, May 7, 2009
- University of Alberta, Edmonton, May 8, 2009
- Toronto - Hospital for Sick Children and St. Michael's Hospital, September 10, 2009

Phase 3 study of denufosol for cystic fibrosis. American Thoracic Society annual meeting, San Diego CA, May 17, 2009.

Childhood asthma. Pediatric Grand Rounds, Community Hospital of Monterey Peninsula, Monterey CA, June 9, 2009.

Atopy in Asthma: Making the Pieces Fit in Clinical Practice. Postgraduate Institute of Medicine/Respiratory & Allergic Disease Foundation CME Teleconference (with Richard J. Martin MD), June 17, 2009.

Inflammation Overview. GlaxoSmithKline CF2110399 Trial Investigators' Meeting, Chicago IL, June 25, 2009.
Achieving Asthma Control: What the 2007 NIH Guidelines Say. Lucile Packard Children's Hospital 17th Annual Pediatric Update, July 17, 2009.

Childhood Asthma: Control and Beyond.
- Abu Dhabi, United Arab Emirates. October 1, 2009
- Al Ain, United Arab Emirates. October 2, 2009
- Dubai, United Arab Emirates. October 3, 2009

Ahead of the Curve: Emerging CF Therapies. Symposium speaker: Overview of Pathophysiologic Targets, North American Cystic Fibrosis Conference, Minneapolis MN, October 16, 2009

Practicalities of Management in Allergic Bronchopulmonary Aspergillosis. North American Cystic Fibrosis Conference, Symposium on Allergy and Asthma in CF (Session Chair), Minneapolis MN, October 17, 2009

New Treatments for Asthma: Anti-IgE and Allergy Shots. Salinas Valley Memorial Hospital pediatric grand rounds, Salinas CA, November 20, 2009

Cystic Fibrosis Lung Disease: Rethinking the At-Risk Patient.
- Albany NY, November 12, 2009
- Children's Hospital Los Angeles, CA, January 15, 2010

Invited Medical School Teaching - Sabbatical in Brazil 2010

São Paulo

- Faculdade de Ciências Médicas da Santa Casa de São Paulo, Santa Casa Hospital. Dr. Luiz Arnaldo Szutan MD PhD, Director, Medical School; Dra. Maria Lucia Bastos Passarell MD PhD, Director, Dept Pediatrics; Dra. Neiva Damasceno, Director Pediatric Pulmonology.
- Universidade Federal de São Paulo (UNIFESP). Dra. Sonia Mayumi Chiba, Director CF Clinic, Prof. Dr. Clovis Eduardo Tadeu Gomes, Chief of Pediatric Pulmonology, Prof. Dr. Mauro Batista de Morais, Chief of Pediatrics.
- Instituto da Criança, Hospital das Clínicas – Medical School of University of São Paulo (FMUSP). Fabiola Villac Adde, MD PhD, Pulmonary Division.

Campinas

- Department of Pediatrics, Dr. Antonio Fernando Ribeiro, Director. FCM da Universidade Estadual de Campinas (UNICAMP)

Rio de Janeiro

- Hospital Universitário Antonio Pedro, Universidade Federal Fluminense (UFF), Niterói. Prof. Beatriz Guitton Renaud B. Oliveira, Professor Titular, Federal Fluminense University School of Nursing, Clinical Research Unit, Course Coordinator.
- Hospital Universitário Pedro Ernesto, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro Centro Biomédico (FCM-UERJ). Prof. Plinio José da Rocha, Dean of Faculty.
- Fernandes Figueira Institute (IFF), Oswaldo Cruz Foundation (FIOCRUZ), Zilton Vasconcelos, Pesquisador em Saúde Adjunto, Laboratório de Fisiopatologia Human.

•Universidade Federal do Rio de Janeiro (UFRJ), Faculdade de Medicina, Programa de Pós-Graduação em Clínica Médica, Clementino Fraga Filho University Hospital, Prof. José Roberto Lapa e Silva, Prof. Pulmonology and Coordinator, UFRJ Graduate Program in Clinical Medicine.
•Oswaldo Cruz Institute (FIOCRUZ) I Simpósio IOC de Fibrose Cística. Giselda M Kalil Cabello PhD, Director, Laboratório de Genética Humana - IOC - Fiocruz.; Daniel Gibaldi, Vinícius Cotta-de-Almeida, Science Committee.
Salvador, Bahia
•Universidade Federal da Bahia (UFBA), Faculdade de Medicina da Bahia, Hospital Especializado Octavio Mangabeira, Dr. Antonio Carlos Moreira Lemos, Chefe do Serviço de Pneumologia.
Belo Horizonte, Minas Gerais
•III Congresso Brasileiro de Fibrose Cistica (1-4 Sept)
Dr. Francisco José-Caldeira Reis, President;
Dra. Neiva Damacena, President, Grupo Brasileiro de Estudos da Fibrose Cistica
•Universidade Federal de Minas Gerais (UFMG), Faculdade de Medicina, Prof. Francisco José Penna, Dean.
Porto Alegre
•Universidade Federal do Rio Grande do Sul (UFRGS)
Santa Casa - Complexo Hospitalar

New Guidelines for the Diagnosis and Treatment of Asthma, Dameron Hospital Association, Stockton CA, May 20, 2011.

Exposure to Aeroallergens, Symposium on the CF Lung and the Environment, 34th European Cystic Fibrosis Conference, Hamburg Germany, June 10, 2011.

Do's and Don't's in the Management of ABPA, Workshop on Immunological Reactions to Fungal Micro-Organisms, 34th European Cystic Fibrosis Conference, Hamburg Germany, June 10, 2011.

ABPA and Nontuberculous Mycobacterial Infection, Physicians Grand Rounds discussant, North American Cystic Fibrosis Conference, Anahaim CA, Nov 3, 2011.

Lessons Learned from the Denufosol Trials. North American Cystic Fibrosis Conference, Anahaim CA, Nov 5, 2011.

Allergic Bronchopulmonary Aspergillosis, Symposium on Fungal Infections, 35th European Cystic Fibrosis Conference, Dublin Ireland, June 9, 2012.

Allergen Sensitization in Allergic Bronchopulmonary Aspergillosis, Plenary Session on Allergy, 18th Congress of the International Society for Human and Animal Mycology, Berlin, June 15, 2012.

Fungal Infection, Allergy and Lung Disease, Pediatric Grand Rounds, Lucile Packard Children's Hospital, Stanford University Medical Center, June 29, 2012.

Chronic Lung Disease of Infancy, American Lung Association of Nevada, Las Vegas, September 13, 2012.

Adult and Childhood Asthma, SEIU UHW-West & Joint Employer Education Conference, Santa Clara CA, October 5, 2012.

APBA Roundtable, North American Cystic Fibrosis Conference, Orlando FL, October 13, 2012.

Early Intervention in Cystic Fibrosis, Johns Hopkins University CME, North American Cystic Fibrosis Conference, Orlando FL, October 11, 2012.

New and Emerging Treatment for Cystic Fibrosis. Rush University CME.
- Spokane WA, November 1, 2012.
- Johns Hopkins Hospital, Baltimore MD, December 10, 2012.

Evidence-Based Therapies in Cystic Fibrosis: Defining the Goals. Rush University CME. Omaha NB, November 8, 2012.

Addressing Advances in the Management of Cystic Fibrosis: CFTR Mutation and Function: Advances in Scientific Knowledge. Potomic Center for Medical Education CME. On-line web course, April 2013.

Aspergillus in CF – what can we learn from other lung diseases? European CF Conference, Lisbon Portugal, June 14, 2013.

Basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis (ABPA) in CF: interim results of a longitudinal cohort study. European CF Conference, Lisbon Portugal, June 14, 2013.

Managing the complexities of cystic fibrosis. Melding evidence-base approaches with expert clinical experience. Rush University CME. Gainesville FL, June 27, 2013.

Asthma Diagnosis and Management. Grand Rounds, Dominican Hospital, Santa Cruz CA, Nov 13, 2013.

Diagnosis and Treatment of ABPA in Children with CF. California Thoracic Society, Carmel CA, Jan 25, 2014.

Fungal Role in Pulmonary Microbiome: *Pseudomonas-Aspergillus* Interaction. 6th Advances Against Aspergillosis Conference, Madrid Spain, February 28, 2014.

Pulmonary Aspergillosis – the Allergic Disease Spectrum. Japanese Respiratory Society 54th Annual Meeting, International Symposium, Osaka Japan, April 26, 2014.

Ivacaftor in Patients with Cystic Fibrosis and the R117H Mutation. European CF Conference, Goteburg Sweden, June 13, 2014.

Effects of Ivacaftor in CF Patients with R117H-CFTR. N Am CF Conference, Atlanta GA, Oct 10, 2014.

ABPA in cystic fibrosis: how is it different from ABPA in asthma? International Society of Human and Animal Mycology, Melbourne Australia, May 6, 2015.

Fungal Infection in Cystic Fibrosis: Onlooker or Player? Pacific Northwest CF Conference. Seattle WA, July 24, 2015.

Fungal Sensitization and Allergic Aspergillosis in Childhood. 7th Advances Against Aspergillosis Conference, Manchester UK, March 3, 2016.

CFTR Modulator Therapy: Lumacaftor-Ivacaftor.

- University of Alberta, Edmonton, Alberta, Canada, October 5, 2016.
- University of Calgary, Calgary, Alberta, Canada, October 6, 2016.
- British Columbia Children's Hospital and Pacific Lung Health Center, Vancouver Canada, November 21, 2016.

The Orkambi Revolution: Hype, Hate or Hope? CF Education Day, Stanford University, March 11, 2017.

Challenging Issues in the Management of CFTR Modulator Therapy: A Case-Based Approach. Spokane WA, April 13, 2017.

Small colony variants of Pseudomonas aeruginsoa display heterogeneity in inhibiting Aspergillus fumigatus biofilm. International Society of Human and Animal Mycology, 4th Working Group on Fungal Infections in Cystic Fibrosis, Osuna Spain, June 6, 2017.

Beyond ABPA. Fungal disease in cystic fibrosis. North American CF Conference, Indianapolis IN, Nov 2, 2017.

Recent advances in diagnosis and treatment of allergic aspergillosis. 8th Advances Against Aspergillosis, Lisbon, Portugal, Feb 2, 2018.

New directions in the treatment of cystic fibrosis: CFTR modulator treatment. Rush University CME lecture series.

- New York NY, June 18, 2018.
- Spokane WA, July 12, 2018.

The spectrum of allergic fungal disease. Grand Rounds, Department of Pediatrics, New York University, Langone NYU Medical Center, Hassenfeld Children's Hospital, New York NY, October 9, 2018.

Allergic bronchopulmonary aspergillosis. Grand rounds, UCLA Mattel Children's Hospital, Los Angeles CA, December 7, 2018.

ResearchCon: Conquering fungal infections and allergy in CF lungs. Cystic Fibrosis Foundation Webinar (presenter), February 28, 2019.

Use of steroids in cystic fibrosis: ABPA and beyond. N Am CF Conference, Nashville TN, October 30, 2019.

The new world of inhaled antifungals and biologics – where might it take us? 9th Advances Against Aspergillosis and Mucormycosis, Lugano Switzerland, Feburary 29, 2020.

Cystic fibrosis and COVID-19: Webcasts with Cystic Fibrosis Research Institute (15 sessions, March 2020-May 2021) https://www.youtube.com/watch?v=kfBkUQr1vZI

Double jeopardy: CF in the Age of COVID-19. CFRI Annual Meeting. CFRI Educational Conference, Redwood City CA, July 30, 2020. https://www.youtube.com/watch?v=B0hYzJ3G97g

Getting to the After Times: CF and Covid in Year 2. CFRI Educational Conference, Redwood City CA, July 31, 2021.

TRAINEES IN ALLERGY-IMMUNOLOGY AND/OR PEDIATRIC PULMONOLOGY
(TRAINING PROGRAM DIRECTOR 1989-1995, 2005-2010)

Name	Current Employment & Location/Certification	Dates of Training
Steven Machtinger MD	Clinical allergy practice San Mateo Clinical faculty, Stanford	1981-3
Russell Leong MD	Clinical allergy practice San Francisco	1981-3
Elide Pastorello MD	Professor, Allergy University of Milan	1982-3 (Visiting Scholar)
Mitchell Seleznick MD	Faculty, allergy-immunology Dept Medicine University of South Florida Tampa, Florida	1982-4
Robert Hindi MD	Clinical allergy practice UCSF	1983-4 (1st yr@ Oakland)
Steven Rubinstein MD	Clinical allergy Sunnyvale Medical Clinic Clinical faculty, Stanford	1983-5
Vivian Saper MD	Clinical faculty, Stanford	1985-6 (1st yr @ UCSF)
Margaret Sullivan MD	Pediatric pulmonology St. Vincent's Hospital New York, NY	1985-6 (2nd yr @St. Vincent's Hosp)
Irmgard Eichler MD	Pediatric pulmonology University of Vienna Associate Professor UMEA, London, 2008-	1986-7 (Visiting Scholar)
Mohan Dhillon MD	Faculty, allergy-immunology Dept Medicine University of Manitoba Winnipeg, Canada	1987-9
Mark Schubert MD, PhD	Clinical allergy practice Clinical faculty Univ Ariz Phoenix, Arizona	1987-9
John Van Wye MD	Clinical allergy practice Ashville, North Carolina	1988-90

Jeffrey Davidson MD	Clinical allergy practice San Francisco	1989-91
Theodore Guarino MD	Pediatric neurologist Los Gatos CA	1989-90
Liesbet Joris-Quinton MD	Division Head Hospital Medicine, Scripps La Jolla CA	1989-90 (Visiting Scholar)
Robert Bocian MD PhD	Clinical faculty, Stanford Palo Alto Medical Foundation	1990-2
Carrie Loutit MD	Clinical Associate Professor Division of General Pediatrics Stanford	1990-2
Syed M. Maseehur Rehman MD	Clinical allergy practice Toledo OH	1990-2
Mary Ann Carmack MD	Clinical infectious disease Palo Alto Medical Foundation	1991
Kevin Schaffer MD	Clinical allergy practice Atlanta, GA	1991-3
Mariska S. Kemna MD	Assistant Professor Pediatric Cardiology University of Washington Seattle Children's Hospital	1991-3 (Visiting Scholar)
Steven Gold MD	Clinical allergy practice Brooklyn NY	1991-3
Luis Antonio Gonzalez MD	Clinical allergy practice El Paso TX	1992-5
Amy Oro MD	Pediatric Practice Los Altos CA	1993-5
Terry Robinson MD	Associate Professor Pediatric Pulmonology Stanford	1993-1996
Peter Maguire MD	Clinical allergy practice Palo Alto Medical Foundation	1994-6
Grace Tamesis MD	Medical Staff National Jewish Hospital & Research Center, Denver CO	1995-6

Kari Nadeau MD PhD	Naddisy Foundation Professor of Pediatric Food Allergy, Immunology and Asthma Professor of Pediatrics Senior Fellow at the Woods Institute for the Environment Professor, by courtesy, of Otolaryngology-Head and Neck Surgery at LPCH Stanford University	2005-6
Shuba Iyengar MD	Clinical allergy practice San Mateo CA	2005-6
Pauline Fani MD	Clinical allergy practice Roslyn NY	2006-7
Jennifer M. Klein MD	Allergist Kaiser Hayward CA	2006-8
Jennifer E. Yoo MD	Allergist Santa Clara Valley Med Center Santa Jose CA	2006-8
Steve J. Song MD	Allergist San Jose, CA	2006-9
Laurence Cheng MD PhD	Assistant Professor Pediatric Allergy UCSF	2006-9
Grace P Yu MD	Allergist Palo Alto Medical Foundation Fremont, CA	2007-10
Katherine Fast MD	Allergist Sutter Health San Francisco, CA	2007-10
Neha Reshamwala MD	Allergist Austin, TX	2008-10
Katharine Nelson MD	Allergist South Bay Allergy and Asthma San Jose, CA	2009-11
Joseph Hernandez MD PhD	Clinical Instructor Pediatric Immunology and Allergy Stanford	2010-13
Yael Gernez MD PhD	Clnical Assistant Professor Pediatrics - Allergy-Immunology Stanford University	2009-14

SELECTED ABSTRACTS

Lewiston NJ, Moss RB. Prolonged corticosteroid therapy in cystic fibrosis. *CF Club Abstr* 22:131, 1981.

Moss RB, Hsu YP. IgM and IgG rheumatoid factors in cystic fibrosis compared to rheumatic diseases of childhood and controls. *Clin Res* 30:96A, 1982.

Moss RB, Hsu YP. Autoimmunity in cystic fibrosis: evidence against polyclonal B cell activation. *J Allergy Clin Immunol* 69:S112, 1982.

Lewiston NJ, Moss RB. Circulating immune complexes decrease during corticosteroid therapy in cystic fibrosis. *Pediatr Res* 16:345A, 1982.

Moss RB, Hsu YP, Leahy M, Halpern G. IgG_4 antibodies to Pseudomonas aeruginosa in cystic fibrosis. *CF Club Abstr* 23:13, 1982.

Leong RE, Moss RB, Blessing J, Cheung NKV, Cheung I, Lewiston NJ. IgE and IgG antibodies to casein in suspected cow's milk allergy. *Ann Allergy* 50:352, 1983.

Moss RB, Hsu YP. Humoral immune response to inhaled and parenteral allergens: role of IgG_4 antibody in clinical protection. *J Allergy Clin Immunol* 73:138, 1984.

Moss RB, Hsu YP, Kwasnicki M, Reid MJ. A quantitative immunoenzymatic assay for allergen-specific IgE antibodies. Comparison with three other in vitro assays. *Clin Res* 32:41A, 1984.

Kwasnicki JM, Moss RB, Cheung NKV, Reid MJ. Towards a quantitative enzyme-linked immunosorbent assay for specific IgE. *J Allergy Clin Immunol* 73:152, 1984.

Blessing J, Leong RE, Machtinger S, Lewiston N, Moss RB. Once a day theophylline in asthmatic adolescents. *Clin Res* 32:61A, 1984.

Blessing J, Leong RE, Machtinger S, Lewiston N, Moss RB, Rubinstein S, Hindi R. Once daily theophylline (Uniphyl) for treatment of bronchospasm in patients with cystic fibrosis and asthma. *Ann Allergy* 52:235, 1984.

Moss RB, Hsu YP. A quantitative immunoenzymatic assay for grass pollen-specific IgG antibodies. *J Allergy Clin Immunol* 75:175, 1985.

Somma C, Silverman E, Moss RB. Normal suppressor T cell function in hospitalized patients with cystic fibrosis. *Clin Res* 33:82A, 1985.

Hindi R, Hsu YP, Moss RB, Lewiston NJ. In vitro screening for allergic antibodies in young children. *Ann Allergy* 54:360, 1985.

Moss RB, Hsu YP. Alveolar macrophage phagocytosis of Pseudomonas aeruginosa opsonized by normal, cystic fibrosis, and murine monoclonal antibodies. *Am Rev Respir Dis* 131:A22, 1985.

Moss RB, Hsu YP, Larrick JW. Opsonization of Pseudomonas aeruginosa by human polyclonal, murine monoclonal, and cystic fibrosis-derived human monoclonal antibodies. *CF Club Abstr* 26:23, 1985.

Adams L, Moss RB, Hindi R, Rubinstein S, Sullivan M, Lewiston N. Effect of nocturnal feeding via percutaneous endoscopic gastrostomy on nutrition and growth in cystic fibrosis. *CF Club Abstr* 26:83, 1985.

Larrick JW, Moss RB, Hart S, Hsu YP, Dyer B. Production of type-specific human monoclonal antibodies to Pseudomonas aeruginosa. *CF Club Abstr* 26:133, 1985.

Moss RB, Hsu YP, Lewiston NJ, De Lange G. Allotype, isotype, and immune response in cystic fibrosis. *J Allergy Clin Immunol* 79:143, 1987.

Moss RB, Hsu YP, Reid MJ. Dissecting the atopic immune response to grass pollen. *J Allergy Clin Immunol* 79:215, 1987.

Moss RB, Hsu YP, Lewiston NJ, De Lange G. Impaired natural IgG_2 antibody response to polysaccharide antigens and decreased Km(1)-A2m(2) allotypes in cystic fibrosis. *Pediatr Res* 21:330A, 1987.

Moss RB, Eichler I. Defective antibody-mediated opsonization of Pseudomonas aeruginosa in cystic fibrosis: an isotype-dependent defect? *J Allergy Clin Immunol* 81:298, 1988.

Moss RB, Kurland G, Ayin S, Lewiston NJ, Cheung ATW. A primate model of chronic Pseudomonas bronchopneumonia. *Am Rev Respir Dis* 137:318, 1988.

Moss R, Joris L, Hsu Y, Eichler I. Role of antigen and isotype in defective opsonization of Pseudomonas aeruginosa in CF. *Pediatr Pulmonol* S2:124, 1988.

Moss RB, Joris L, Hsu YP, Van Wye J, Eichler I. Are IgG_4 antibodies to lipopolysaccharide antigens of Pseudomonas aeruginosa opsonophagocytic blocking factors in cystic fibrosis? *American Association for the Advancement of Science, Annual Meeting Abstracts,* p. 59, 1989.

Moss RB, Joris L, Eichler I, Van Wye J, Hsu YP. Pseudomonas aeruginosa endobronchial infection in cystic fibrosis induces nonopsonic IgG_2 and IgG_4 lipopolysaccharide-specific antibodies. *Pediatr Res* 25:185A, 1989.

Cheung ATW, Moss RB, Lewiston NJ, Leong A, Novick WJ. Chronic Pseudomonas endobronchitis and pentoxifylline efficacy study. *Am Rev Respir Dis* 141:A87, 1990.

Hsu YP, Moss RB. Performance of a microtiter plate histamine release assay employing a monoclonal antibody. *J Allergy Clin Immunol* 87:280, 1991.

Bocian RB, Hsu YP, Van Schooten W, Gardner P, Nghiem P, Moss RB. Antigen-specific T cell clones from cystic fibrosis patients. *Pediatr Pulmonol* Suppl 6:304, 1991.

Moss RB, Loutit CL, Davidson J, Hsu YP. Mechanism of β-lactam induced mediator release in CF. *Pediatr Pulmonol* Suppl 6:306, 1991.

Bocian R, Hsu YP, Kemna M, Dong A, Gardner P, Moss R. Phenotypic characterization of T cell clones derived from patients with cystic fibrosis. *Pediatr Pulmonol* Suppl 8: 318, 1992.

Kemna M, Hsu YP, Bocian R, Moss R. Expression of CFTR in T cells: demonstration by flow cytometry and catalytic immunoprecipitation. *Pediatr Pulmonol* Suppl 8: 318, 1992.

Bocian RC, Hsu Y-P, Kemna M, Dong Y, Gardner P, Moss RB. Cystic fibrosis transmembrane conductance regulator expression in T cell clones from cystic fibrosis patients. *Am Rev Respir Dis* 147: A26 and A718, 1993.

Lim JJ, Moss RB, Palmer J, Harkins EA, Marcus R, Bachrach LK. Bone mineral status in cystic fibrosis: risk factors for osteoporosis. *Pediatr Pulmonol* Suppl 9:278, 1993.

Moss R, Desch J, King V, Toy KJ, Sinicropi D, Shak S. Biochemical and biophysical characterization of sinus secretions in CF. *Pediatr Pulmonol* Suppl 9:266, 1993.

Bocian RC, Hsu Y-P, Kemna M, Olds L, Dong Y, Gardner P, Moss RB. Direct demonstration of CFTR protein expression and Cl^- channel dysregulation in cystic fibrosis T cells. *Pediatr Pulmonol* Suppl 9:204, 1993.

Moss R, Bocian R, Hsu Y-P, Yssel H. Is CF a T_H2 immunoinflammatory disease? *Pediatr Pulmonol* Suppl 9:289, 1993.

Hamilton JR, Noble A, Moss RB, Bocian RC. Synergy testing in antibiotic selection for cystic fibrosis patients with multi-resistant Pseudomonas. *Pediatr Pulmonol* Suppl 9:262, 1993.

Sinicropi D, Prince W, Lofgren JA, Baker D, Moss R, Smith AL, Shak S. Measurement of DNA concentration and length in cystic fibrosis sputum. *Pediatr Pulmonol* Suppl 10:238, 1994.

Gonzalez A, Troup N, Mickelsen P, Moss R. Pseudomonas aeruginosa in sinuses and airways of CF patients: genomic fingerprinting by pulsed field gel electrophoresis. *Pediatr Pulmonol* Suppl 10:252-253, 1994.

Moss R, Fink R, Schroeder S, Ramsey B, Fries L, Fuller S, Harkonen S, Muenz L, Thornton M. Safety and pharmacokinetics of a mucoid Pseudomonas aeruginosa immune globulin intravenous in patients with cystic fibrosis - preliminary results of a Phase I/II trial. *Pediatr Pulmonol* 19:85, 1995.

Moss RB, Bocian RC, Hsu YP, Wie T, Yssel H. Reduced interleukin-10 production by cystic fibrosis T cell clones. *Am J Resp Crit Care Med* 151:A248, 1995.

Harkins EA, Moss RB, Umbenhower D. Critical pathway for management of pulmonary exacerbation in cystic fibrosis reduces cost and length of stay. *Am J Resp Crit Care Med* 151: A741, 1995.

Robinson TE, Sarinas PS, Clark AR, Chitkara R, Moss RB, Canfield J, Corkery K, Fick RB. Effect of device resistance and dynamic lung function on peak inspiratory flow rates in CF and non-CF COPD. *Am J Resp Crit Care Med* 151:A837, 1995.

Moss R, Hsu Y, Wei T, Bocian R. Interleukin-10 is selectively reduced in activated cystic fibrosis T lymphocytes. *Pediatr Pulmonol* Suppl 12:273-274, 1995.

Olds L, Hsu Y, Wei T, Bocian R, Fok K, Wada G, Moss R. T cell activation and cytotoxicity in cystic fibrosis. *Pediatr Pulmonol* Suppl 12:274, 1995.

Wagner JA, Daifuku R, Moran ML, Kouyama K, Palmer J, Norbash AM, Harkins A, Davies Z, Reynolds T, Guggino WB, Moss RB, Wine JJ, Carter BJ, Flotte TR, Gardner P. Evaluation of adeno-associated virus mediated gene transfer of CFTR in the maxillary sinus of CF patients with antrostomies. *Pediatr Pulmonol* Suppl 12:227, 1995.

Mickle J, Macek M, Egan M, Fulmer-Smentek S, Schwiebert E, Guggino W, Moss R, Cutting G. Elevated sweat chloride concentrations in the absence of lung or pancreatic manifestations are associated with mutations in each CFTR gene. *Pediatr Pulm* Suppl 13:245, 1996.

Wagner JA, Moran ML, Messner AH, Daifuku R, Kouyama K, Desch JK, Norbash AM, Harkins A, Friborg S, Reynolds T, Guggino WB, Moss RB, Wine JJ, Carter BJ, Flotte TR, Gardner P. Safety of delivery of adeno-associated virus medated gene transfer of CFTR in the maxillary sinus of CF patients with antrostomies. *Pediatr Pulm* Suppl 13:276, 1996.

Moss RB, Nepomuceno I, Esrig S. Allergic bronchopulmonary aspergillosis in cystic fibrosis: aeroallergen sensitization and treatment with itraconazole. *Pediatr Pulm* Suppl 13:327, 1996.

Moss RB, YP Hsu YP, L Olds L. Reduced IL-10 secretion by T cells expressing mutant CFTR: a role for Ca^{2+} and Cl^- channels. *J Allergy Clin Immunol* 99:S330, 1997.

Moss R, Nepomuceno I, Esrig S. Efficacy of itraconazole for allergic bornchopulmonary aspergillosis in cystic fibrosis. *Am J Resp Crit Care Med* 155:A644, 1997.

Moss RB, Hsu YP, Olds L. Reduced IL-10 secretion by T cells expressing mutant CFTR is mimicked by inhibition of Cl^- flux. *Am J Resp Crit Care Med* 155:A198, 1997.

Dosanjh A, Kawalek A, Moss R. The activation of eosinophils in the airways of lung transplantation patients. *AmJ Resp Crit Care Med* 155:A270, 1997.

Robinson T, Leung AN, Moss RB, Bloch DA, Northway WH. Cystic fibrosis: evaluation of a thin-section CT scoring system. Radiological Society of North America, annual meeting, Nov 30-Dec 5, 1997.

Wagner JA, Moran ML, Messner AH, Daifuku R, Desch JK, Norbash AM, Conrad CK, Nepumuceno I, Manley S, Friborg S, Reynold T, Guggion WB, Moss RB, Wine JJ, Carter BJ, Flotte TR, Gardner P. Efficient and persistent gene transfer of AAV-CFTR in the maxillary sinus of CF patients with antrostomies. *Pediatr Pulmonol* Suppl 14:267, 1997.

Robinson TE, Leung AN, Moss RB, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Northway WH. Assessment of spirometer-gated high resolution computed tomography of the chest in cystic fibrosis patients before and after treatment for a pulmonary exacerbation. *Pediatr Pulmonol* Suppl 17:334-335, 1998.

Wagner JA, Messner AH, Friborg S, Reynolds T, Guggino WB, Moss RB, Wine JJ, Carter BJ, Flotte TR, Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF in the maxillary sinus of CF patients. *Pediatr Pulmonol* Suppl 17:260, 1998.

Robinson TE, Leung AN, Moss RB, Blankenberg FG, Northway WH. A new technique for evaluating air-trapping in CF patients using spirometer-gated high resolution CT scans during inspiratory/expiratory imaging. *Pediatr Pulmonol* Suppl 17:335, 1998.

Wagner JA, Moran ML, Messner AH, Nepomuceno IB, Norbash AM, Conrad CK, Moss RB, Wine JJ, Gardner P. Maxillary sinusitis as a surrogate model for acute infectious exacerbations of CF lung disease. *Pediatr Pulmonol* Suppl 17:351, 1998.

Robinson TE, Leung AN, Moss RB, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Northway WH. Utility of spirometer-triggered high resolution computed tomography scores in assessing changes in cystic fibrosis patients before and after treatment for a pulmonary exacerbation. *Pediatr Research* 45:355A, 1999.

Frick OL, Gertz E, Wong JH, del Val G, Yee BC, Buchanan BB, Petersen WR, Teuber SS, Moss R. New evidence strengthening the dog as a model for human allergies. *J Allergy Clin Immunol* 103:S98, 1999.

Moss R, Kylstra JW, Gibson R. Who benefits more? An analysis of FEV1 and weight in adolescent (age 13-<18) CF patients using inhaled tobramycin (Tobi). *Pediatr Pulmnol* Suppl 19:243, 1999.

Wagner JA, Messner AH, Moran ML, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Batson EP, Moss RB, and Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in CF patients with antrostomies. *Pediatr Pulmnol* Suppl 19:223, 1999.

Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A Phase I study of aerosolized administration of tgAAVCF to CF patients with mild lung disease. *Pediatr Pulmnol* Suppl 20:236, 2000.

Stroud P, Paxton C, Moss RB. Widespread underdiagnosis and non-CF Center based care for California CF patients. *Pediatr Pulmnol* Suppl 20:316, 2000.

Robinson TE, Germain-Thomas AS, Kesavarju K, Northway WH, Leung AN, Moss RB. Spirometer-triggered high resolution computed tomography scores in mild and moderate to severe CF lung disease. *Am J Respir Crit Care Med* 163:A87, 2001.

Robinson TE, Germain-Thomas AS, Kesavarju K, Oehlert JW, Bloch DA, Moss RB. Quantitative air trapping analysis in children with mild cystic fibrosis pulmonary disease. *Am J Respir Crit Care Med* 163:A564, 2001.

Tirouvanziam RM, Tjioe I, Moss RB, Parks DR, Herzenberg LA, Wine JJ. Multiparameter study of CF blood and lung leucocytes using 3-laser, 11-color flow cytometry. *Pediatr Pulmonol* Suppl 22:271-272, 2001.

Robinson TE, Kesavaraju K, Newaskar M, Bhise P, Mishra N, Blankenberg FG, Northway WH, Leung AN, Moss RB. Spirometer-triggered high-resolution computed tomography scores in mild and moderate to severe CF lung disease. *Pediatr Pulmonol* Suppl 22:301, 2001.

Goris ML, Zhu JH, Moss RB, Robinson TE. An automated method for air trapping quantification utilizing inspiratory and expiratory CT images. *Am J Respir Crit Care Med* 165:A650, 2002.

Moss R, Aitken M, Clancy J, Milla C, Rodman D, Spencer LT, Waltz D, Zeitlin P, Davies Z, Hamblett N, Johnson C, Pedersen P, Carlin J. .A multicenter, double-blind, placebo controlled, phase II study of aerosolized tgAAVCF in cystic fibrosis patients with mild lung disease. *Pediatr Pulmonol* Suppl 24: 250-251, 2002.

Robinson T, Leung AN, Northway WH, Blankenberg FG, Chan F, Bloch D, Homes T, Moss RB. Composite spirometric-CT outcome measure markedly improves sensitivity to change in early cystic fibrosis lung disease. *Pediatr Pulmonol* Suppl 24: 298, 2002.

Robinson TE, Goris ML, Bhise P, Sathi A, Zhu JH, Moss RB. Quanititative HRCT air trapping analysis in CF subjects with mild lung disease during a Pulmozyme intervention study. *Pediatr Pulmonol* Suppl 24: 298, 2002.

Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfield M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Moss R, Konstan M, Retsch-Bogart G, Waltz D, Wilmott R, Wagener J, Zeitlin P, Ramsey B. A randomized, controlled tiral of inhaled tobramycin in young children with cystic fibrosis: eradication of Pseudomonas aeruginosa from the lower airway. *Pediatr Pulmonol* Suppl 24: 300, 2002.

Moss R, Wagener J, Daines C, Hale K, Ahrens R, Gibson R, Anderson K, Retsch-Bogart G, Nasr S, Noth I, Waltz D, Zeitlin P, Ramsey B, Hamblett N, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b (IFN-g1b) effects on safety, bacterial counts, and pulmonary function in 66 patients with mild-moderate cystic fibrosis lung disease. *Am J Respir Crit Care Med* 167:A923, 2003.

Brody AS, Campbell JD, Millard, Steven P, Moss RB, Heald AE. Relationship between FEV1 and high-resolution chest CT findings in CF patients with mild lung disease: baseline data from the AAV2 Phase II gene transfer study. *Pediatr Pulmonol* Suppl 25; 319, 2003.

Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan M, Wagener JG. Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann C, Aitken M, Mahl T Safety and preliminary clinical activity of a novel pancreatic enzyme preparation, Theraclec-Total for the treatment of exocrine pancreatic insufficiency. *Pediatr Pulmonol* Suppl 25; 339, 2003.

Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Hamblett N, Borowitz D, Daines C, Hiatt P, Konstan M, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Zeitlin PL, Ramsey B. Duration of the anti-pseudomonal treatment effect of inhaled tobramcyin in young children with cystic fibrosis. *Pediatr Pulmonol* Suppl 25; 295, 2003.

Robinson TE, Goris ML, Zhu JH, Valansani M, Kabanskaya Y, Moss RB. Regional effects of Pulmozyme therapy on air trapping during a 12 month intervention. *Pediatr Pulmonol* Suppl 25; 315-316, 2003.

Robinson TE, Goris ML, Zhu JH, Chen X, Moss RB. Quantitative air trapping is associated with mucus plugging, extent and severity of bronchial wall thickness and bronchiectasis HRCT scoring. *Pediatr Pulmonol* Suppl 25; 316, 2003.

Robinson TE, Raman R, Venkatraman R, Desai N, Shah S, Mishra N, Alper A, Sheikh F, Hajra S, Nadgir U, Nandini A, Moss RB. Effect of Pulmozyme therapy on quantitative airway measurements: results of a preliminary study. *Am J Respir Crit Care Med* 169:A391, 2004

Wong T, Delaria K, Tepper J, Moss R, Longphre M. SPINT2 inhibits elastase activity in bronchoalveolar lavage fluids from CF patients. *Pediatr Pulmonol* Suppl 27:256, 2004

Moss RB, Milla C, Colombo J, Clancy JP, Zeitlin P, Spencer T, Accurso F, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Martin D, Anklesaria P. Heald AE. A mulicenter, double-blind, placebo-controlled, Phase IIB study of aerosolized tgAAVCF for the treatment of cystic fibrosis. *Pediatr Pulmonol* Suppl 27:257-258, 2004

Robinson T, Brody AS, Raman R, Venkatraman R, Rubin G, Alper A, Chen X, Dastagir A, Moss R. Protocol optimization for low dose volumetric CT in CF children. *Pediatr Pulmonol* Suppl 27:304, 2004

Borowitz D, Goss C, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan M, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann C, Aitken M, Mahl T, Dunitz J Clancy JP. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation, TheraCLEC-Tota,l containing lipase, protease and amylase for the treatment of exocrine pancreatic insufficiency. Eur CF Conf 2004.

Moss RB, Heald AE and the 25E01 Study Group. A randomized phase IIB study of aerosolized tgAAVCF for treatment of cystic fibrosis. *Am J Respir Crit Care Med* 171:A179, 2005.

Moss RB, Heald AE and the 25E01 Study Group. Phase IIB study of aerosolized tgAAVCF for cystic fibrosis. *J Cystic Fibrosis* 4: S27, 2005.

Tirouvanziam R, Conrad C, Dunn C, Davies Z, Aram B, Bottiglieri T, Moss R, Herzenberg L.
High-dose N-acetylcysteine as a systemic antioxidant and potent inhibitor of lung inflammation in CF: A pilot phase 1 trial. *Pediatr Pulmonol* Suppl 28:263, 2005.

Tirouvanziam R, Conrad CK, Dunn C, Davies Z, Gernez Y, Aram B, Moss R, Herzenberg L. Phase 2 trial of high-dose oral N-acetylcysteine as a systemic antioxidant and inhibitorof lung inflammation. *Pediatr Pulmonol* Suppl 29:295, 2006.

Gernez Y, Conrad CK, Moss RB, Herzenberg LA, Tirouvanziam R. Single-cell phosphoepitope profiling in live blood and sputum neutrophils brings insights into CF inflammatory pathophysiology. *Pediatr Pulmonol* Suppl 29:268, 2006.

Rosenfeld M, Emerson J, Uh D, Anderson G, Genatossio, McNamara S, Dunn C, Davies Z, Foster J, Kantor E, Moss R, Burns J, Aitken M, Gibson R. Does tobramycin accumulate in respiratory secretions with repeated aerosol administration: a pilot study. *Pediatr Pulmonol* Suppl 29:327, 2006.

Robinson TR, Chen X Moss R. Chest HRCT scoring better discriminates the effects of bacterial colonization/infection on disease severity in children with mild CF lung disease. *Pediatr Pulmonol* Suppl 29:342, 2006.

Clancy JP, MW Konstan, SM Rowe, F Accurso, P Zietlin, R Moss, Z Bebok, VJ Northcutt, GL Elfring, LL Miller, S Hirawat. A Phase 2 study of PTC124 in CF patients harboring premature stop mutations. *Pediatr Pulmonol* Suppl 29:301, 2006.

Yuan N, Kane P, Shelton K, Matel J, Becker B, Moss RB. A pilot study of polysomnography to evaluate effectiveness of airway clearance therapies in pediatric patients with cerebral palsy and neuromuscular disorders. *Chest* 132:609S, 2007.

Yuan N, Kane P, Shelton K, Matel J, Becker B, Moss RB. A pilot study: high-frequency chest-wall oscillation and standard chest physiotherapy in cerebral palsy and neuromuscular weakness disorder patients. *Am J Respir Crit Care Med* 177:A273, 2008.

Yuan N, Kane P, Shelton K, Matel J, Becker B, Moss RB. A comparison of adherence to therapy in high-frequency chest-wall oscillation and standard chest physiotherapy in cerebral palsy and neuromuscular weakness disorders. *Am J Respir Crit Care Med* 177:A114, 2008.

Moss RB, Anbar RD, Wilmot RW, Barnes M, Schaberg AE, Durham TA, FJ Accurso FJ. Phase 3 study of denufosol tetrasodium for the treatment of cystic fibrosis. *Am J Respir Crit Care Med* 179:A1189, 2009.

Neshamwala NR, Song SJ, Yu GP, Swamy S, Berquist W, Nguyen T, Hoyte EG, Vissametti S, Sivagnanasundraram AM, Saper VE, Hwang PH, Moss RB, Nadeau KC. Study of sublingual immunotherapy in subjects with *Dermatophagoides farinae* and Timothy grass allergy. *J Allergy Clin Immunol* 123:S126, 2009.

Accurso FJ, Rowe SM, Durie PR, Konstan MW, Dunitz J, Hornick DB, Sagel SD, Boyle MP, Uluer AZ, Moss RB, Ramsey BW, Freedman SD, Dong Q, Zha J. Stone AJ, Olson ER, Ordonez CL, Clancy JP, Campbell PW, Ashlock MA. Final results of a 14- and 28-day study of VX-770 in subjects with CF. *J Cystic Fibrosis* 8;Suppl 2:S25, 2009.

Accurso FJ, Rowe SM, Durie PR, Konstan MW, Dunitz J, Hornick DB, Sagel SD, Boyle MP, Uluer AZ, Moss RB, Ramsey BW, Freedman SD, Dong Q, Zha J. Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Clancy JP. Improvement in sweat chloride concentration by the CFTR potentiator VX-770 in patients with cystic fibrosis and the G551D-CFTR mutation. *Pediatr Pulmonol* 44; Suppl 32:296, 2009.

Clancy JP, Rowe SM, Durie PR, Konstan MW, Dunitz J, Hornick DB, Sagel SD, Boyle MP, Uluer AZ, Moss RB, Freedman S, Dong Q, Zha J, Stone A, Olson E, Ordonez C, Campbell P, Ashlock M, Accurso FJ. Comparison of NPD parameters in a phase IIa study to optimize detection of CFTR modulator bioactivity in clinical trials. *Pediatr Pulmonol* Suppl 33:301, 2010.

Navratil T, Evans C, Schaberg A, Johnson F, Durham T, Smiley L, Herje N, Burke B, Ren CL, Ratjen F, Moss RB, Accurso FJ. Denufosol Tetrasodium – An Investigational Inhaled Therapy with Aerosol and Pharmacokinetic Properties Suitable for Early Intervention in CF Lung Disease. *Am J Respir Crit Care Med* 181:A6581, 2010.

Moss RB, Schaberg A, Deans C, Tian W, Xue X, Smiley L, Navratil T, Durham T, Accurso FJ. Denufosol improved lung function and was well tolerated in adolescents with cystic fibrosis. *Pediatr Pulmonol* Suppl 33:310, 2010.

Tirouvanziam R, Aronov P, Laval J Makam M, Liu C, Chien A, Herzenberg L, Gronert K, Moss RB. Small metabolite profiling of airway fluid uncovers specific alterations in CF. *Pediatr Pulmonol* Suppl 33:243, 2010.

Ratjen F, Navratil T, Evans C, Schaberg A, Durham T, Ren C, Moss R, Accurso F. Denufosol aerosol properties, pharmacokinetics & efficacy & safety profiles demonstrates its potential as early intervention for cystic fibrosis lung disease. *Pediatr Pulmonol* Suppl 33:317, 2010.

Rowe SM, van Goor F, Clancy JP, Durie PR, Konstan MW, Dunitz J, Hornick DB, Sagel SD, Boyle MP, Uluer AZ, Moss RB, Ramsey B, Freedman S, Dong Q, Zha J, Stone A, Olson E, Ordonez C, Campbell P, Ashlock M, Accurso. FJ.

Corresponding effects of VX-770 on NPD in vivo & human bronchial epithelial cells in vitro. *Pediatr Pulmonol* Suppl 33:319, 2010.

Davies Z, Dunn CE, Hernandez C, Zirbes J, Milla C, Moss RB. Survey to assess research satisfaction at Stanford. *Pediatr Pulmonol* Suppl 33:401, 2010.

Ratjen F, Accurso F, Moss R, Navratil T, Schaberg A, Durham T. Potential of denufosol as an early intervention therapy for CF lung disease. *Experimental Biology 2010*

SM Rowe SM, FJ Accurso FJ, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewsk JM, Rubenstein R, Uluer AZ, Aitken ML, Dong Q, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW. Improvement in ion transport biomarkers and spirometry with the investigational CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-*CFTR* mutation. *International Congress on Pediatric Pulmonology 2010.*

Nguyen H, Hoyte EG, Vissamsetti S, Siva AM, Saper VE, Hwang PH, Moss RB, Nadeau KC. Mechanistic studies of tolerance in sublingual immunotherapy patients with Dermatophagoides farniae and timothy grass allergy. *Federation of Clinical Immunology Societies 2010.*

Navratil T, Evans C, Schaberg A, Johnson F, Durham T, Ren CL, Ratjen F, Moss RB, Accurso FJ. Aerosol and pharmacokinetic properties of denufosol support its use for early intervention in CF lung disease. *J Cystic Fibrosis* 9 Suppl 1:S21, 2010.

Moss RB, Schaberg A, Deans C, Tian W, Smiley L, Herje N, Durham T, Accurso F. Denufosol improves lung function in adolescent CF patients. *J Cystic Fibrosis* 9 Suppl 1:S20, 2010.

Donaldson SH, Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. Improved CFTR and lung function with VX-770, a novel oral potentiator of CFTR, in subjects with the G551D-CFTR mutation. *European Respiratory Society 2010.*

Tirouvanziam R, Laval J, Gudiputi L, Touhami J, Battini J-L, Conrad C, Milla C, Moss R, Sitbon M, Herzenberg L. Metabolic conditioning and reprogramming are hallmarks of neutrophilic inflammation in cystic fibrosis. *Inflammation 2011* (June 2011, Paris).

Gernez Y, Tirouvanziam R, Dunn C, Davies Z, Herzenberg L, Moss R. Basophil CD203c as a potential clinically relevant biomarker in cystic fibrosis and allergic bronchopulmonary aspergillosis. *J Cystic Fibrosis* 10; Suppl 1:S46, 2011.

Gernez Y, Tirouvanziam R, Dunn CE, Everson C, Davies Z, Herzenberg LA, Moss RB. CD203c and CD63 expression in blood basophils discriminate between CF patients with *Aspergillus* colonization and those with CF-ABPA. *Pediatr Pulmonol* Suppl 34:241, 2011.

Gudiputi L, Aronov P, Makam M, Zirbes J, Conrad C, Milla C, Herzenberg L, Moss R, Tirouvanziam R. Metabolite profiling of CF airway fluid suggests a role for catecholamines in early and chronic disease. *Pediatr Pulmonol* Suppl 34:240-241, 2011.

Luke-Zeitoun M, Nielson DW, Desch J, Moss RB. Effectiveness of individualized non-supervised coached exercise program in children with cystic fibrosis. *American Thoracic Society* 2012: A5263, 10.1164/ajrccm-conference.2012.185.1. MeetingAbstracts.A5263.

Gernez Y, Tirouvanziam R, Dunn CE, Everson C, Davies Z, Herzenberg LA, Moss RB. Specific induction of CD203c expression in blood basophils discriminates between CF patients with *Aspergillus* colonization and those with CF-ABPA. *American Academy of Allergy Asthma and Immunology 2012 Annual Meeting,* Featured Poster Presentation. *J Allergy Clin Immunol* 129: AB139, 2012.

Gernez Y, Everson C, Dunn CE, Fernandez-Becker N, Gudiputi L, Davies ZA, Herzenberg LA, Tirouvanziam R, Moss RB. Modulatory effects of *Aspergillus* colonization and ABPA on blood and sputum eosinophils and neutrophils in CF. *European CF Conference 2012*, platform presentation. *J Cyst Fibrosis* 11 Suppl 1:S20, 2012.

Moss RB, Waters J, Dunn C, Davies Z, Everson C, Tirouvanziam R, Tameresis J, Herzenberg LA, Gernez Y. Basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis (ABPA) in CF: interim results of a longitudinal cohort study. *European CF Conference 2013*, platform presentation. *J Cyst Fibrosis* 12 Suppl 1:S46, 2013.

Wine JJ, Char J, Jeong J, Dunn C, Davies Z, Moss RB. Ivacaftor increases R117H CFTR function in vivo: increased CFTR-dependent secretion from identified sweat glands. *Pediatr Pulmonol* Suppl 36:281, 2013.

Ferreira JAG, Nazik H, Penner JC, Clemons KV, RMoss RB, Banaei N, Stevens DA. *Pseudomonas aeruginosa* inhibition of *Aspergillus fumigatus* is dependent on the source, phenotype and growth conditions of the bacterium. *Advances Against Aspergillosis 2014*, Abstracts #51.

Penner JC, Nazik H, Clemons KV, Stevens DA, Moss RB, Banaei N, Ferreira JAG. *Aspergillus fumigatus* (Af) biofilm and the effect of *Pseudomonas aeruginosa* (Pa) phenotypes. *Advances Against Aspergillosis 2014*, Abstract #49.

Gernez Y, Waters J, Everson C, Hernandez C, Herzenberg LA, Moss RB. Differential upregulation of surface dectin-1 expression on sputum neutrophils in CF-ABPA. *Advances Against Aspergillosis 2014*.

Gernez Y, Waters J, Dunn C, Davies Z, Tirouvanziam R, Everson C, Tamaresis J, Herzenberg L, Moss RB. Basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis: one year results of a longitudinal cohort study. *J Allergy Clin Immunol* 133: AB58, 2014.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M, on behalf of the VX11–770-110 (KONDUCT) Study Group. Ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study. *European CF Conference 2014*, platform presentation. *J Cyst Fibrosis* 13:S44, 2014.

Sabino R, Ferreira JAG, Moss R, Valente J, Veríssimo C, Carolino E, Clemons KV, Banaei N, Penner J, Stevens DA. Molecular epidemiology of Aspergillus from Cystic Fibrosis patients. *54th Interscience Conference on Antimicrobial Agents and Chemotherapy* 2014, Abstract M-1088.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Pilewski J, Higgins M. Effects of ivacaftor in CF patients with *R117H-CFTR. N American CF Conference* 2014, *Pediatr Pulmonol* 2014; Suppl 38:221.

Char JE, Dunn CE, Davies Z, Milla CE, Wine JJ, Moss RB. Estimating ivacaftor effects on R117H CFTR open probability: human in vivo measurements. *N American CF Conference* 2014, *Pediatr Pulmonol* 2014; Suppl 38:291.

Lavelle GM, Mirkovic B, Azim AA, Helma K, Gargoum FS, Molloy K, Gernez Y, Dunne K, Renwick J, Murphy P, Moss RB, Greene CM, Gunaratman C, Chortirmall SH, McElvaney NG. The basophil surface marker CD203c identifies *Aspergillus fumigatus* sensitization in cystic fibrosis. *Pediatr Pulmonol* Suppl 41:227, 2015.

Moss R, Miller S, Mayer-Hamblett N, Goss CH, Morgan W, Pasta D, McKone E, Sawicki G, Konstan M, Wagener J. Long-term rates of lung function decline in patients with CF and the R117H or homozygous F508del CFTR gene mutation. 2015 N Am CF Conf, *Pediatr Pulmonol* 2015; Suppl 41:353.

Wagener J, Sawicki G, Miller S, Mayer-Hamblett N, Goss CH, Moss R, Morgan W, Pasta D, McKone E, Konstan M. Rate of lung function decline in patients with cystic fibrosis and the R117H mutation. 2015 N Am CF Conf, *Pediatr Pulmonol* 2015; Suppl 41:347.

Anand R, Moss R, Banaei N, Clemons KV, Stevens DA. Small colony variants of *Pseudomonas aeruginosa* display heterogeneity in inhibiting *Aspergillus fumigatus* biofilm. Program of the 7th Advances Against Aspergillosis meeting, Manchester, U.K., 2016, Abstracts, no. 44.

Nazik, H, Moss RB, Karna V, Clemons KV, Banaei N, Cohen K, Choudhary V, Stevens DA. Are cystic fibrosis Aspergillus fumigatus isolates different? Program of the 7th Advances Against Aspergillosis meeting, Manchester, U.K., 2016, Abstracts, no. 40.

Gernez Y, Waters J, Mirkovic B, Lavelle FM, Dunn CE, Davies Z, Everson C, Silver E, Wallenstein S, Chotirmall SH, McElvaney NG, Herzenberg LH, Moss RB. Modulatory Effects of Aspergillus colonization and ABPA on blood and sputum granulocytes in CF. 2016 American Academy of Allergy, Asthma and Immunology annual meeting. *J Allergy Clin Immunol* 137; AB29, 2016.

Sullivan JC, Accurso FJ, Marigowada G, Beusmans J, Geho D, Zhang E, Moss RB, Waltz D. Improvement in inflammatory biomarkers in patients with cystic fibrosis (CF) homozygous for *F508del-CFTR* mutation treated with lumacaftor and ivacaftor. 2016 European Cystic Fibrosis Conference. *J Cystic Fibros* 15; Suppl 1:S6, 2016.

Konstan MW, McKone E, Moss R, Marigowda G, Cooke J, Lubarsky B, Rubin J, Millar S, Pasta D, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki G. Evidence of sustained benefit and reduction in annual rate of lung function decline from combination lumacaftor and ivacaftor therapy in patients ≥12 years of age with cystic fibrosis homozygous for the *F508del-CFTR* mutation. 2016 European Conference on Rare Diseases and Orphan Products.

Sullivan JC, Accurso FJ, Marigowada G, Beusmans J, Geho D, Zhang E, Moss RB, Waltz D. Combination lumacaftor/ivacaftor therapy improves inflammatory biomarkers in patients with the F508del-CFTR mutation. 2016 N Am CF Conf. *Pediatr Pulmonol* Suppl 45:274-275, 2016.

Konstan MW, McKone E, Moss R, Marigowda G, Cooke J, Lubarsky B, Rubin J, Millar S, Pasta D, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki G. Evidence of reduction in annual rate of FEV1 decline and sustained benefits with lumacaftor and ivacaftor in patients aged ≥12 with CF homozygous for F508del-CFTR. 2016 N Am CF Conference. *Pediatr Pulmonol* Suppl 45:260, 2016.

Sawicki GS, Konstan M, McKone E, Moss RB, Johnson C, Lubarksy B, Suthoff E, Millar S, Pasta DJ, Mayer-Hamblett N, Goss C, Morgan W. Rate of lung function decline in patients with cystic fibrosis having a residual function gene mutation. Am Thoracic Society annual meeting, May 2017.

Anand R, Moss RB, Banaei N, Clemons KV, Martinez M, Stevens DA. Small colony variants of Pseudomonas aeruginsoa display heterogeneity in inhibiting Aspergillus fumigatus biofilm. International Society of Human and Animal Mycology, 4th Working Group meeting on Fungal Infections in Cystic Fibrosis, Osuna Spain, June 6, 2017.

Konstan MW, McKone EF, Moss RB, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki G. Relationship between rate of percent predicted FEV1 decline and baseline and acute change in percent predicted FEV_1 in patients with cystic fibrosis treated with lumacaftor/ivacaftor. European CF Society annual meeting, June 2017.

Sawicki GS, Konstan MW, McKone EF, Moss RB, Lubarksy B,Suthoff E, Millar SJ,Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan WJ. Rate of lung function decline in patients with cystic fibrosis having a residual function gene mutation. American Thoracic Society annual meeting, poster A4847, May 2017.

Robinson TE, Goris ML, Moss RB, Tian L, Kan P, Yilma M, McCoy KS, Newman B, de Jong PA, Long FR, Brody AS, Behrje R, Yates DP, Wielpütz MO, Cornfield DN. Differential sensitivity of outcome measures that assess progression of mild CF lung disease in school age children. European CF Society annual meeting, June 2017. *J Cystic Fibros* 16 Suppl 1:EPS4.3, 2017.

Sawicki GS, Konstan MW, McKone E, Moss RB, Suthoff E, LeCamus C, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan. Burden of illness in individuals with cystic fibrosis and a residual function mutation. N Am CF Conference, poster, November 2017.

Vaeth S, Moss R. Impact of short-term individual psychotherapy for CF patients and families on depression and anxiety. N Am CF Conference, November 2017. *Pediatr Pulmonol* 52 Suppl 47:475, 2017.

Sawicki GS, Konstan MW, McKone E, Moss RB, Lubarsky B, Suthoff E. Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W. Rate of lung function decline in patients with cystic fibrosis having a residual function gene mutation. Poster 255, British Thoracic Society, December 2017.

Vaeth S, Moss RB. Impact of online wellness classes for both CF patients and CF caregivers on depression and anxiety, N Am CF Conference 2019. *Pediatr Pulmonol* 54 Suppl 2:397-398, 2019.

Hong G, Moss RB, Marshall B, Quon B, Eschenhagen P, Schwarz C. ECFS/CFF global survey on diagnosis and treatment of *Aspergillus fumigatus*-related conditions. *J Cystic Fibrosis* 19:Suppl 2, S55-56, 2020.

Hong G, Moss RB, Lomas PH, Marshall B, Quon B, Eschenhagen P, Schwarz C. ECFS/CFF global survey of the diagnosis and treatment of *Aspergillus fumigatus*-related conditions in cystic fibrosis. N Am CF Conference 2020 poster 293. *Pediatr Pulmonol* 55 Suppl 2:154, 2020.

Li BC, Huh S, Prieto M, Hong G, Schwartz C, Moss RB, Quon B. Biomarkers for the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis: a systematic review and meta-analysis. N Am CF Conference 2020, pôster 455. *Pediatr Pulmonol* 55 Suppl 2:216, 2020.

Lee I, Moss RB. Potential novel variant nephronophthisis with pediatric end-stage renal disease and bronchiectasis. Am J Resp Crit Care Med 2021:203:A3382

Lee I, Lee J, Moss R. Late diagnosis of cystic fibrosis and omalizumab toxicity in a pediatric patient with acute allergic bronchopulmonary aspergillosis and vocal cord dysfunction. Am J Respir Crit Care Med 2022; https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A4382

PEER-REVIEWED PUBLICATIONS

1. Miller JJ, Hsu YP, **Moss RB**, Olds L. The immunologic and clinical associations of the split products of C'3 in plasma in juvenile rheumatoid arthritis. *Arth Rheum* 22:502-507, 1979.

2. O'Leary J, **Moss RB**, King R, Liebhaber M, Lewiston N. Cuirass ventilation in childhood neuromuscular disease. *J Pediatr* 94:419-421, 1979.

3. **Moss RB**, Sriram S, Kelts KA, Lewiston N. Chronic neuropathy presenting as a floppy infant with respiratory distress. *Pediatrics* 64:459-464, 1979.

4. **Moss RB**, Lewiston NJ. Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. *Am Rev Respir Dis* 121:23-29, 1980.

5. **Moss RB**, Hsu YP, Lewiston NJ. ^{125}I-C1q binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. *J Pediatr* 99:215-222, 1981.

6. **Moss RB**, Hsu YP. Isolation and characterization of circulating immune complexes in cystic fibrosis. *Clin Exp Immunol* 47:301-308, 1982.

7. Hsu YP, **Moss RB**. A microtiter immunoenzymatic assay for antigen-specific IgG$_4$ subclass antibodies. *Clin Rev Allergy* 1:233-236, 1983.

8. Hsu YP, **Moss RB**. Microtiter plate immunoassays for IgE and IgG subclass antibodies. *Immunol Allergy Pract* 6:56-64, 1984.

9. Ortolani C, Pastorello E, **Moss RB**, Hsu YP, Restuccia M, Joppolo G, Miadonna A, Cornelli U, Halpern G, Zanussi C. Grass pollen immunotherapy. A single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. *J Allergy Clin Immunol* 73:283-290, 1984.

10. **Moss RB**, Babin S, Blessing J, Lewiston NJ. Allergy to semisynthetic penicillins in cystic fibrosis. *J Pediatr* 104:460-466, 1984.

11. Rubinstein S, Hindi R, **Moss R**, Blessing J, Lewiston N. Sudden death in adolescent asthma. *Ann Allergy* 53:311-318, 1984.

12. Reid MJ, Kwasnicki JM, **Moss RB**, Cheung NKV. Underestimation of specific immunoglobulin E by microtiter plate enzyme-linked immunosorbent assays. *J Allergy Clin Immunol* 76:172-177, 1985.

13. **Moss RB**, Blessing J, Bender SW, Weibel A. Cystic fibrosis and neuroblastoma. *Pediatrics* 76:814-817, 1985.

14. Lewiston NJ, **Moss RB**. Immune complexes in CF: keys to new clinical insight. *J Respir Dis* 7:60-66, 1986.

15. Machtinger S, **Moss RB**. Cow's milk allergy in breast fed infants. Role of allergen and breast milk secretory IgA antibody. *J Allergy Clin Immunol* 77:341-347, 1986.

16. **Moss RB**, Hsu YP, Lewiston NJ, Curd JG, Milgrom H, Hart S, Dyer B, Larrick JW. Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. *Am Rev Respir Dis* 133:648-652, 1986.

17. **Moss RB**, Hsu YP, Sullivan MM, Lewiston NJ. Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. *Pediatr Res* 20:453-459, 1986.

18. Sullivan MM, **Moss RB**, Lewiston NJ. Supraventricular tachycardia in cystic fibrosis. *Chest* 90:239-242, 1986.

19. Rubinstein S, **Moss RB**, Lewiston NJ. Constipation and meconium ileus equivalent in cystic fibrosis. *Pediatrics* 78:473-79, 1986.

20. Reid MJ, **Moss RB**, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal asthma in northern California: allergic etiology and efficacy of immunotherapy. *J Allergy Clin Immunol* 78:590-600, 1986.

21. **Moss RB**. Antibody and immune complex production in cystic fibrosis. *Pediatr Pulmonol Suppl 1*:95-98, 1987.

22. **Moss RB**. IgG subclass antibody markers in grass pollen immunotherapy. *Allergy Proceed* 8:409-415, 1987.

23. **Moss RB**, Hsu YP, Kwaswnicki JM, Sullivan MM, Reid MJ. Isotypic and antigenic restriction of the blocking antibody response to Rye grass pollen: correlation of Rye Group I specific IgG_1 with clinical response. *J Allergy Clin Immunol* 79:387-398, 1987.

24. **Moss RB**. Hypergammaglobulinemia in cystic fibrosis: the role of Pseudomonas endobronchial infection. *Chest* 91:522-526, 1987.

25. Lewiston NJ, Hindi R, Hsu YP, Lewiston J, **Moss RB**. IgE antibodies in young children with possible allergic symptoms. *J Pediatr* 110:738-40, 1987.

26. Lewiston NJ, **Moss RB**, Hindi R, Rubinstein S, Sullivan MM. Interobserver variance in clinical scoring for cystic fibrosis. *Chest* 91:878-82, 1987.

27. **Moss RB**, Hsu Y, Esrig S. Performance characteristics of immunoenzymatic testing for total and specific immunoglobulin E. Comparison of conventional assay with a microtiter plate accelerated computerized procedure. *Ann Allergy* 59:185-191, 1987.

28. **Moss RB**, Hsu YP, Van Eede PH, Van Leeuwen AM, Lewiston NJ, De Lange G. Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens. *Pediatr Res* 22:708-713, 1987.

29. Terr AI, **Moss RB**, Strober S. Effect of total lymphoid irradiation on IgE antibody responses in rheumatoid arthritis and systemic lupus erythematosus. *J Allergy Clin Immunol* 80:798-802, 1987.

30. **Moss RB**. The role of IgG subclass antibodies in chronic infection: the case of cystic fibrosis. *Allergy Proceed* 9:57-61, 1988.

31. **Moss RB**. Allergy evaluation in children: skin testing and RAST. *Am J Asthma Allergy Pediatr* 1:101-108, 1988.

32. Smith AL, Redding G, Doershuk C, Goldman D, Gore E, Hilman B, Marks M, **Moss R**, Ramsey B, Rubio T, Schwartz R, Thomassen MJ, Williams-Warren J, Weber A, Wilmott R, Wilson D, Yogev R. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. *J Pediatr* 112:547-554, 1988.

33. Reid MJ, Schwietz LA, Whisman BA, **Moss RB**. Mountain cedar pollenosis: can it occur in non-atopics? *Allergy Proceed* 9:225-232, 1988.

34. Eichler I, Gotz M, Jarisch R, **Moss R**. Assessment of validity of allergen reactivity with multiple skin prick testing, RAST, EAST, and rocket immunoelectrophoresis. *Allergy* 43:458-463, 1988.

35. **Moss RB**. Allergic etiology and immunology of asthma. *Ann Allergy* 63:566-577, 1989.

36. Fling JA, Ruff ME, Parker WA, Whisman BA, Martin ME, **Moss RB**, Reid MJ. Suppression of the late cutaneous response by immunotherapy. *J Allergy Clin Immunol* 83:101-109, 1989.

37. Palmer J, Parker BR, **Moss R**, Lewiston NJ. Bird fancier's disease in children. *Am J Asthma Allergy Pediatr* 3:45-52, 1989.

38. Eichler I, Joris L, Hsu YP, Van Wye J, Bram R, **Moss RB**. Nonopsonic antibodies in cystic fibrosis: Pseudomonas aeruginosa lipopolysaccharide-specific antibodies from infected patients inhibit neutrophil oxidative responses. *J Clin Invest* 84:1794-1804, 1989.

39. **Moss RB**. Antibody production in cystic fibrosis and possibilities for immunotherapy. *Pediatr Pulmonol Suppl* 5: 66-67, 1990.

40. Umetsu DT, **Moss RB**, King VV, Lewiston NJ. Sinus disease in patients with cystic fibrosis: relationship to pulmonary exacerbation. *Lancet* 335:1077-1078, 1990.

41. Van Wye JE, Collins MS, Baylor M, Pennington JE, Hsu YP, Sampanvejsopa V, **Moss RB**. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. *Pediatr Pulmonol* 9:7-18, 1990.

42. Northway WH, **Moss RB**, Carlisle KB, Parker BR, Popp RL, Pitlick PT, Eichler I, Lamm R, Brown BW. Late pulmonary sequelae of bronchopulmonary dysplasia. *N Engl J Med* 26:1793-1799, 1990.

43. **Moss RB**. IgG subclasses. *West J Med* 154:458-459, 1991.

44. **Moss RB**. Drug allergy in cystic fibrosis. *Clin Rev Allergy* 9:211-229, 1991.

45. Van Wye JE, Hsu YP, Lane RS, Terr AI, **Moss RB**. Anaphylaxis from a tick bite. *N Engl J Med* 324:777-778, 1991.

46. **Moss RB**. Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. *J Allergy Clin Immunol* 87:78-88, 1991.

47. **Moss RB**, McClelland E, Rubio T, Hillman B, Williams R, Adkinson NF. In vivo and in vitro evaluation of immunologic cross-reactivity of aztreonam in cystic fibrosis patients allergic to penicillin and/or cephalosporin antibiotics. *Rev Infect Dis* 13: S598-S607, 1991.

48. Van Wye JE, Hsu YP, Lane RS, Terr AI, **Moss RB**. IgE antibodies in tick bite-induced anaphylaxis. *J Allergy Clin Immunol* 88: 968-970, 1991.

49. King VV, **Moss RB**. The role of sinus surgery in chronic sinusitis in children. *Am J Allergy Asthma Pediatr* 5:203-208, 1992.

50. **Moss RB**, Carmack MA, Esrig S. Deficiency of IgG_4 in children: association of isolated IgG_4 deficiency with recurrent respiratory tract infection. *J Pediatr* 120:16-21, 1992.

51. Schubert MS, **Moss RB**. Selective polysaccharide antibody deficiency in familial Di George syndrome. *Ann Allergy* 69: 231-8, 1992.

52. Cheung ATW, **Moss RB**, Leong AB, Novick WJ. Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: I. Effect of pentoxifylline on neutrophil influx. *J Med Primatol* 21:357-362, 1992.

53. Cheung ATW, **Moss RB**, Kurland G, Leong, Novick WJ. Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: II. A histophathologic analysis. *J Med Primatol* 22:257-262, 1993.

54. **Moss RB**. Passive immuntherapie fur die behandlung der endobronchitis bei zysticher fibrose. *Infusionsther Transfusionsmed* 20 (suppl 1): 42-47, 1993.

55. Ramsey BW, Boat T, Accurso F, Bennett W, Boucher R, Brody A, Crystal R, Cutting G, Davis P, Dorkin H, Fleming T. Kaplan R, Knowles M, Konstan M, Laube B, McElvaney G, Morgan W, **Moss R**, Orenstein R, Pencharz P, Rosenstein B, Schidlow D, Smith A, Spino M, Stallings V, Stecenko A, Terrin M, Weatherly M, Wilmott R, Wilson C, Wood R. Outcome measures for clinical trials in cystic fibrosis. *J Pediatr* 124:177-92, 1994.

56. Bachrach L, Loutit C, **Moss R**, Marcus R. Osteopenia in adults with cystic fibrosis. *Am J Med* 96:27-34, 1994.

57. Fuchs HJ, Borowitz DS, Christiansen DH, et al for the Pulmozyme® Study Group (member). Aerosolized recombinant human DNase reduces respiratory exacerbations and improves pulmonary function in patients with cystic fibrosis. *N Engl J Med* 331:637-42, 1994.

58. **Moss RB**. New drugs for cystic fibrosis lung disease. *West J Med* 1995; 162:354-355.

59. **Moss RB**. Inflammatory response in cystic fibrosis lung disease. *New Insights into Cystic Fibrosis* 3:1-6, 1995.

60. **Moss RB**. Alternative pharmacotherapies for steroid-dependent asthma. *Chest* 107: 817-825, 1995.

61. **Moss RB**, King VV. Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage: reduction in recurrence requiring surgery. *Arch Otolaryngol - Head Neck Surg,* 121: 566-572, 1995.

62. Dong Y, Chao AC, Kouyama K, Hsu YP, Bocian RC, **Moss RB**, Gardner P. Activation of CFTR chloride channel by nitric oxide in human T lymphocytes. *Eur Molec Biol Org J,* 14: 2700-2707, 1995.

63. Spector SL & Nicklas RA, Eds., Joint Task Force on Practice Parameters (member). Practice parameters for the diagnosis and treatment of asthma. *J Allergy Clin Immunol* 96: 707-870, 1995.

64. **Moss RB**. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. *Clin Infect Dis* 21:839-851, 1995.

65. Bhudhikanok GS, Lim J, Marcus R, Harkins A, **Moss RB**, Bachrach LK. Correlates of osteopenia in patients with cystic fibrosis. *Pediatrics* 97: 103-111, 1996.

66. Wilmott RW, Amin RS, Colin A, Devault A, Dozor AJ, Eigen H, Johnson C, Lester LA, McCoy K, McKean LP, **Moss R**, Nash ML, Pagel Jue C, Regelmann W, Stokes DC, Fuchs HJ. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. *Am J Respir Crit Care Med* 153:1914-1917, 1996.

67. **Moss R**. Pathways to inflammation in cystic fibrosis. *Pediatr Pulmnol* Suppl 13:158-160, 1996.

68. **Moss RB**, Bocian RC, Hsu YP, Dong Y, Wei T, Kemna M, Gardner P. Reduced interleukin- 10 secretion by CD4+ T lymphocytes expressing mutant CFTR. *Clin Exp Immunol* 106: 374-388, 1996.

69. **Moss RB**. When to use a HEPA filter for atopic childhood asthma. *J Respir Dis* 17:806, 1996.

70. **Moss RB**. Immune therapies for lung infection in cystic fibrosis. *IACFA Newsletter* 46:8-13, 1996.

71. Eisenberg J et al, for the Aerosolized Tobramycin Study Group (member). A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. *Chest* 111:955-962, 1997.

72. Dosanjh A, Kawalek A, **Moss RB**. Activation of eosinophils in the airways of lung transplantation patients. *Chest* 112:1180-1183, 1997.

73. Mickle JE, Macek M, Fulmer-Smentek SB, Egan MM, Schwiebert E, Guggino W, **Moss R**, Cutting GR. A mutation in the cystic fibrosis transmembrane conductance regulator associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. *Human Molec Genet* 7:729-735, 1998.

74. Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, Guggino WB, **Moss RB**, Carter BJ, Wine JJ, Flotte TR, Gardner P. A phase I/II study of tgAAV-CFTR for the treatment of chronic sinusitis in patients with cystic fibrosis. *Hum Gene Ther* 9:889-909, 1988.

75. Bhudhikanok GS, Wang M-C, Marcus R, Harkins A, **Moss RB**, Bachrach LK. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. *J Pediatrics* 133:18-27, 1988.

76. Wagner JA, Moran ML, Messner AH, Diafuku R, Kouyama D, Desch JK, Manley S, Norbash AM, Kang S, Conrad CK, Friborg S, Reynolds T, Guggino WB, **Moss RB**, Carter BJ, Wine JJ, Flotte TR, Gardner P. Efficient and persistent gene transfer of AAV-CFTR in the CF maxillary sinus. *Lancet* 351: 1702-1703, 1998.

77. Wagner JA, Moran ML, Messner AH, Diafuku R, Kouyama D, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, **Moss RB**, Carter BJ, Wine JJ, Flotte TR, Gardner P. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. *Laryngoscope* 109: 266-274, 1999.

78. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev M, et al for the Cystic Fibrosis Inhaled Tobramycin Study Group (member). Chronic intermittment administration of inhaled tobramycin in patients with cystic fibrosis. *N Engl J Med* 340: 23-30, 1999.

79. Nepumuceno I, Esrig S, **Moss RB**. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. *Chest* 115: 364-370, 1999.

80. Wagner JA, Nepumuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, **Moss RB,** Wine JJ, Gardner P. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials. *J Gene Med* 1:13-21, 1999.

81. Smith AL, Doershuk C, Goldman D, Gore E, Hilman B, Marks M, **Moss R**, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson D, Yogev R. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. *J Pediatrics* 134:413-421, 1999.

82. Robinson TE, Leung AN, **Moss RB**, Blankenberg FG, Northway, WH. Standardized high-resolution CT of the lung using a spirometer-gated electron beam CT scanner. *Am J Roentgenol* 172:1636-1638, 1999.

83. Wagner JA, Vassilakis A, Yee K, Li M, Hurlock G, Krouse ME, **Moss RB**, Wine JJ. Two novel CFTR mutations in a cystic fibrosis patient of Chinese origin. *Hum Genet* 104:511-515, 1999.

84. Lane RS, **Moss RB**, Hsu YP, Wei T. Anti-arthropod saliva antibodies among residents of community at high risk for Lyme disease in California. *Am J Trop Med Hygiene* 61:850-859, 1999.

85. Illek B, Zhang L, Lewis NC, **Moss RB**, Dong J-Y, Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. *Am J Physiol* 277: C833-C839, 1999.

86. Yee K, Robinson C, Hurlock G, **Moss RB**, Wine JJ. Novel cystic fibrosis mutation L1093P: functional analysis and possible Native American origin. *Human Mutation* 15:208, 2000.

87. **Moss RB**, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis peripheral lymphocytes. *Clin Exp Immunol* 120: 518-525, 2000.

88. Howling SJ, Northway WH Jr, Hansell DM, **Moss RB**, Ward S, Muller NL. Pulmonary sequelae of bronchopulmonary dysplasia survivors: high-resolution CT findings. *AJR Am J Roentgenol* 174:1323-1326, 2000.

89. Wine JJ, Kuo E, Hurlock G, **Moss RB**. Comprehensive mutation screening in a cystic fibrosis center. *Pediatrics* 107: 280-286, 2001.

90. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Bloch DA, Oehlert JW, Al Dabbagh H, Hubli S, **Moss RB**. Spirometer-triggered high-resolution CT and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. *J Pediatrics* 138:553-559, 2001.

91. **Moss RB**. Administration of aerosolized antibiotics in cystic fibrosis patients. *Chest* 120:107S-113S, 2001.

92. Aitken ML, **Moss RB**, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A phase I study of aerosolized administration of tgAAVCF to CF subjects with mild lung disease. *Hum Gene Ther* 12:1907-1916, 2001.

93. **Moss RB**. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. *Chest* 121:55-63, 2002.

94. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, **Moss RB**, Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in CF patients with antrostomies. *Human Gene Therapy* 13:1349-1359, 2002.

95. **Moss RB**. Allergic bronchopulmonary aspergillosis. *Clinical Reviews in Allergy* 23:87-104, 2002.

96. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, **Moss R**, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B; Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. *Am J Respir Crit Care Med* 167:841-849, 2003.

97. Steinbach WJ, Stevens DA, Denning DW, **Moss RB**. Introduction: Advances against Aspergillosis. *Clinical Infectious Diseases* 37 (Suppl 3):S1-2, 2003.

98. Stevens DS, **Moss R**, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody A, Light M, Skov M, Maish G, Mastella G, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Cystic Fibrosis Foundation Consensus Conference. *Clinical Infectious Diseases* 37 (Suppl 3): S225-S264, 2003.

99. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, Holmes TH, **Moss RB.** Composite spirometric-CT outcome measure markedly improves sensitivity to change in early cystic fibrosis lung disease. *Am J Respir Crit Care Med* 168:588-593, 2003.

100. **Moss RB**, Rodman D, Spencer LT, Aitkin ML, Zeitlin PL, Waltz D, Milla C, Brody A, Clancy JP, Ramsey B, Hamblett N, Heald A. Repeated AAV2 aerosol-mediated CFTR gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. *Chest* 125:509-521, 2004.

101. Dorsaneo D, Borowitz D, Sharp J, **Moss R**. Allergic bronchopulmonary aspergillosis with normal serum IgE in a child with cystic fibrosis. *Ped Asthma Allergy Immunol* 17:146-150, 2004.

102. **Moss RB**. Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. *Clin Exp Immunol* 135:358-360, 2004.

103. Bonnel AS, Song, SMH, Kesavarju K, Newaskar M, Paxton CJ, Bloch DA, **Moss RB**, Robinson TE. Quantitative air trapping analysis in children with mild cystic fibrosis lung disease. *Pediatr Pulmonol* 38:396-405, 2004.

104. Schrijver I, Karnsakul W, Ramalingam S, Sankaran R, **Moss R**, Gardner P. Novel contributions to the Asian CFTR mutation spectrum: genotype and phenotype in Thai patients with cystic fibrosis. *Am J Med Genet* 133A:103-105, 2005.

105. Schrijver I, Ramalingam S, Sankaran R, Swanson S, Dunlop CLM, Keiles S, Wassman EF, **Moss RB**, Oehlert J, Gardner P, Kammesheidt. Diagnostic testing by comprehensive mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum. *J Molec Diagnostics* 7:289-299, 2005.

106. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sathi A, Sheikh F, **Moss RB**. Dornase alpha reduces air trapping in children with mild CF lung disease: a quantitative analysis. *Chest* 128:2327-2335, 2005.

107. **Moss RB**, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz DA, Zeitlin P, Ramsey B, , Starko K. A randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. *Pediatr Pulmonol* 39:209-218, 2005.

108. **Moss RB**. Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. *Medical Mycology* 43: S203-S206, 2005.

109. Xiao W, Hsu YP, Ishizaka A, Kirikae T, **Moss RB**. Sputum cathelicidin, plasmin activation system components and cytokine patterns discriminate cystic fibrosis, chronic obstructive pulmonary disease and asthma from each other and healthy subjects. *Chest* 128:2316-2326, 2005.

110. Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan M, Wagener J, **Moss R**, et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. *Pancreas* 32:258-263, 2006.

111. Venkatraman R, Raman R, Raman B, **Moss RB**, Rubin GD, Mathers LH, Robinson TE. Fully automated system for three-dimensional bronchial morphology analysis using volumetric multidetector computed tomography of the chest. *J Digit Imaging* 19:132-9,2006.

112. Kurup VP, Knutsen AP, **Moss RB**, Bansal N. Demonstration of specific antibodies to recombinant *Aspergillus* allergens in cystic fibrosis patients with ABPA. *Clin Molec Allergy* 4:11-18, 2006.

113. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, **Moss RB**, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. *Proc Natl Acad Sci USA* 103:4628-4633, 2006.

114. **Moss RB**. Critique of trials in allergic bronchopulmonary aspergilllosis and fungal allergy. *Med Mycol* 44: S269-S272, 2006.

115. Wang L, Xiao W, **Moss RB**, Hsu YP. Urokinase-type plasminogen activator system in induced sputum from patients with bronchial asthma. *Chinese J TB Resp Dis* 29, 124, 2006.

116. Gibson RL, Emerson J, Hamblett N, Burns JL, McNamara S, Accurso F, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz D, Acton J, Zeitlin P, Hiatt P, **Moss R**, Williams J, Ramsey BW for the Inhaled Tobramycin in Young Children Study Group and the Cystic Fibrosis Foundation Therapeutics Development Network. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. *Pediatr Pulmonol* 42:610-623, 2007.

117. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson RL, Zeitlin P, Berclaz Y, **Moss R**, Knowles M, Oster RA, Mayer-Hamblett N, Ramsey B. No detectable improvements in CFTR by nasal aminoglycosides in CF patients heterozygous for stop mutations. *Am J Respir Cell Mol Biol* 37:57-66, 2007.

118. **Moss RB**, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled Phase IIB trial. *Human Gen Ther* 18:726-732, 2007.

119. Tirouvanziam R, Gernez, Y, Conrad CK, **Moss RB**, Schrijver I, Dunn CE, Davies ZA, Herzenberg LA, Herzenberg Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. *Proc Natl Acad Sci U S A* 105:4335-4339, 2008.

120. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW; Inhaled Tobramycin in Young Children Study Group (**R Moss**, member); Cystic Fibrosis Foundation Therapeutics Development Network. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. *J Pediatr* 154:183-188, 2009.

121. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; EPIC Study Group (**R Moss**, member). Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observation study. *Contemp Clin Trials* 30:256-268, 2009.

122. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (**R Moss**, member); North American Scientific Advisory Group for ESCF. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. *J Pediatr* 155:634-9.e1-4, 2009.

123. Banner K, De Jonge H, Elborn S, Growcott E, Gulbins E, Konstan M, **Moss R**, Poll C, Randell SH, Rossi AG, Thomas L, Waltz D. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. *J Cystic Fibrosis* 8:1-8, 2009.

124. **Moss RB**. Infection, inflammation and the downward spiral of cystic fibrosis lung disease. *J Pediatr* 154:162-163, 2009.

125. Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, Dunn CE, Davies ZA, **Moss RB,** Herzenberg LA, Herzenberg LA, Tirouvanziam R. Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. *Proc Natl Acad Sci U S A* 106:5779-83, 2009.

126. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, et al; Gene Modifier Study Group (**Moss R**, member). Genetic modifiers of liver disease in cystic fibrosis. *JAMA* 302:1076-83, 2009.

127. Robinson TE, Leung AN, Chen X, **Moss RB,** Emond MJ. Cystic fibrosis HRCT scores correlate strongly with *Pseudomonas* infection. *Pediatr Pulmonol* 44:1107-1117, 2009.

128. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, Tullis E, et al; Cystic Fibrosis Related Diabetes Therapy Study Group (**Moss R**, member). Insulin therapy to improve BMI in cystic fibrosis related diabetes without fasting hyperglycemia: results of the Cystic Fibrosis Related Diabetes Therapy Study Group. *Diabetes Care* 32:1783-8, 2009.

129. Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, et al; EPIC Study Group Participating Clinical Sites (**Moss R**, member). Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. *Pediatr Pulmonol* 45:934-44, 2010.

130. Yuan N, Kane P, Shelton K, Matel J, Becker B, **Moss RB**. Safety, tolerability and efficacy of high frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular disorders: an exploratory randomized controlled trial. *J Child Neurology* 25:815-21, 2010.

131. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, **Moss RB**, Pilewsk JM, Rubenstein R, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D mutation. *N Eng J Med* 363:1991-2003, 2010.

132. Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis **(R Moss**, member). Socioeconomic status and the likelihood of antibiotic treatment for signs and symptos of pulmonary exacerbation in children with cystic fibrosis. *J Pediatr* 159:819-824.e1, 2011.

133. Accurso FJ, **Moss RB**, Wilmott RW, Anbar RD, Schaberg AE, Durham TA, Ramsey BW; TIGER-1 Investigator Study Group. Denufosol tetrasodium by inhalation in patients with cystic fibrosis and mild pulmonary function impairment. *Am J Respir Crit Care Med* 183:627-34, 2011.

134. Ramsey BW, Plant B, Davies J, Tullis E, Bell S, Dřevínek P, Griese M, Konstan M, **Moss R**, Sermet-Gaudelus I, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn S, and the VX-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 365:1663-1672, 2011.

135. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW; Early Pseudomonas Infection Control (EPIC) Investigators (**R Moss**, member). Comparative efficacy and safety of 4 randomized regimes to treat early Pseuomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 165:847-856, 2011.

136. Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators (**R Moss**, member). Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 47:125-134, 2012.

137. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballman M, Boyle MP, Campbell PW, Bronsveld I, DeBoeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Lebecque P, McCoy KS, **Moss RB**, Pilewskin JM, Rosenbluth D, Rubinstein RC, Schechter MS, Botfield M, Cu Y, Ordonez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Results of a Phase 2a study of VX-809, an investigational CFTR corrector compound, in cystic fibrosis subjects homozygous for the F508del-CFTR mutation. *Thorax* 67:12-8, 2012.

138. Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, Greenberger PA, Kariuki B, Kita H, Kurup VP, **Moss RB**, Niven RM, Pashley CH, Slavin RG, Vijay HM, Wardlaw AJ. Fungi and allergic lower respiratory tract disease. *J Allergy Clin Immunol* 129:280-91, 2012.

139. Ratjen F**,** Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, **Moss RB,** the TIGER-2 Study Investigator Group. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. *J Cyst Fibros* 11:539-549, 2012.

140. Gernez Y, Dunn CE, Everson C, Mitsunaga E, Gudiputi L, Krasinska K, Davies ZA, Herzenberg LA, Tirouvanziam R, **Moss RB**. Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by *Aspergillus* allergens. *J Cyst Fibros* 11:502-510, 2012.

141. **Moss RB.** The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. *Annals NY Acad Sci* 1272:49-57, 2012.

142. Ruddy J, Emerson J, **Moss R**, Genatossi A, McNamara S, Burns JL, Anderson G, Rosenfeld M. Tobramycin concentrations in respiratory secretions of cystic fibrosis patients with repeated administration of inhaled tobramycin. *J Aero Med Pulm Drug Deliv* 26:69-75, 2103.

143. **Moss RB**, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer RM, Lazaar AL; for the CF2110399 Investigators. Safety and early treatment effects of trhe CXCR2 antagonist SB-656933 in patients with cystic fibrosis. *J Cyst Fibros* 12:241-248, 2013.

144. **Moss RB.** Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. *J Pediatrics* 162:676-680, 2013.

145. Batista MV, Costa SF, Shikanai-Yasuda M, **Moss RB**. Current treatment options for invasive aspergillosis. *Drugs of Today* 49:213-226, 2013.

146. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, **Moss R,** Denning DW. Allergic bronchopulmonary aspergillosis: review of the literature and proposal of new diagnostic and classification criteria. *Clin Exp Allergy* 43:850-873, 2013.

147. Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordoñez CL, Stone AJ, Olson ER, Clancy JP; VX06-770-101 Study Group (**R Moss**, member). Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. *PLoS One* 8: e66955, 2013.

148. Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators (**R Moss**, member). Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. *Pediatr Pulmonol* 48:943-953, 2013.

149. **Moss RB**. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. *Eur Respir J* 43:1487-1500, 2014.

150. Konstan MW, Döring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton A; Investigators and Coordinators of BI Trial 543.45 (**Moss R**, member). A randomized, double-blind, placebo-controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. *J Cyst Fibros* 13:148-55, 2014.

151. Char JE, Wolfe MH, Cho H, Park I, Jeong J, Frisbee E, Dunn C, Davies Z, Milla C, **Moss RB**, Thomas EAC, Wine JJ. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. *PLoS One* 9: e88564, 2014.

152. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group (**Moss R**, member). Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomized, double-blind, placebo-controlled phase 3 trial. *Lancet Respir Med* 2:539-47, 2014.

153. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group (**Moss R**, member). A CFTR corrector (lumacaftor and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomized controlled trial. *Lancet Respir Med* 2:527-38, 2014.

154. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC; VX08-770-105 (PERSIST) Study Group (**Moss R**, member). Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). *Lancet Respir Med* 2:902-10, 2014.

155. Chmiel JF, Konstan MW, Accurso FJ, Lymp J, Mayer-Hamblett N, VanDevanter DR, Rose LM, Ramsey BW; Assessment of Induced Sputum in Cystic Fibrosis Study Group (**Moss R**, member). Use of ibuprofen to assess inflammatory biomarkers in induced sputum: implications for clinical trials in cystic fibrosis. J Cyst Fibros 14:720-6, 2105.

156. Conrad C, Lymp J, Thompson V, Dunn C, Davies Z, Chatfield B, Nichols D, Clancy J, Vender R, Egan ME, Quitell L, Michelson P, Antony V, Spar J, Rubinstein RC, **Moss RB**, Herzenberg L, Goss C, Tirouvanziam R. Long-term treatment with oral N-acetylcysteine affects lung function but not sputum inflammation in cystic fibrosis subjects. A Phase II randomized placebo-controlled trial. *J Cyst Fibros* 14:219-227, 2015.

157. Sanders DB, Emerson J, Ren CL, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group (**Moss R**, member). Early childhood risk factors for decreased FEV1 at age six to seven years in young children with cystic fibrosis. Ann Am Thorac Soc 12:1170-6, 2015.

158. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group (**Moss R**, member). Lumacaftor-ivacacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. *N Engl J Med* 373:220-31, 2015.

159. Sabino R, Ferreira JA, **Moss RB**, Valente J, Verissimo C, Carolino E, Clemons KV, Banaei N, Penner J, Stevens DA. Molecular epidemiology of Aspergillus collected from cystic fibrosis patients. *J Cyst Fibros* 14:474-81, 2015.

160. **Moss RB**. Fungi in CF and non-CF bronchiectasis. *Semin Resp Crit Care Med* 36:207-216, 2015.

161. Milla CE, **Moss RB.** Recent advances in cystic fibrosis. *Curr Opin Pediatr* 27:317-324, 2015.

162. Ferreira JAG, Penner JC, **Moss RB**, Haagensen JA, Clemons KV, Nazik H, Cohen K, Banaei N, Stevens DA. *Pseudomonas aeruginosa* inhibition of *Aspergillus fumigatus* and its biofilm is dependent on the source, phenotype and growth conditions of the bacterium. *PLoS One* 10: e0134692, 2015.

163. **Moss RB**, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M. Efficacy and safety of ivacaftor treatment in patients with cystic fibrosis who have an R117H mutation. *Lancet Resp Med* 3:524-33, 2015.

164. Kharrazi M, Yang J, Bishop T, Lessing S, Young S, Graham S, Pearl M, Chow H, Ho T, Currier R, Gaffney L, Feuchtbaum L; California Cystic Fibrosis Newborn Screening Consortium (**Moss R**, member). Newborn screening for cystic fibrosis in California. *Pediatrics* 136:1062-72, 2015.

165. Mirković B, Lavelle GM, Azim AA, Helma K, Gargoum FS, Molloy K, Gernez Y, Dunne K, Murphy P, **Moss RB,** Greene CM, Gunaratnam C, Chotirmall SH, McElvaney NG. The basophil surface marker CD203c identifies *Aspergillus* sensitization in cystic fibrosis. *J Allergy Clin Immunol* 137:436-43.e9, 2016.

166. Gernez Y, Waters J, Dunn C, Davies Z, Everson C, Silver E, Wallenstein S, Herzenberg LA, **Moss RB**. Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. *Eur Resp J* 47:177-85, 2016.

167. Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis **(Moss R**, member). Forced expiratory volume in 1 second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function. *J Pediatr* 169:116-21, 2016.

168. **Moss RB**. Treating allergic aspergillosis: the way forward. *Eur Respir J* 47:385-7, 2016.

169. Stevens DA, **Moss RB**, Hernandez C, Clemons KV, Martinez M. Effect of media modified to mimic cystic fibrosis sputum on the susceptibility of *Aspergillus fumigatus*, and the frequency of resistance at one center. *Antimicrob Agents Chemother* 60:2180-4, 2016.

170. Orlova DY, Zimmerman N, Meehan S, Meehan C, Waters J, Ghosn EEB, Filatenkov A, Kolyagin GA, Gernez Y, **Moss RB**, Herzenberg LA, Walther G. Quantitative analysis of multivariate changes in biomarkers measured by flow cytometry. *PLOS One* 11(3): e0151859, 2016.

171. Tracy MC, Foley EA, Okorie CUA, **Moss RB**. Allergic bronchopulmonary aspergillosis. *J Fungi* 2:17, 2016.

172. Gernez Y, Waters J, Tirouvanziam R, Herzenberg LA, **Moss RB**. Basophil activation test determination of CD63 combined with CD203c is not superior to CD203c alone in identifying ABPA in cystic fibrosis, *J Allergy Clin Immunol* 38:1195-6, 2016.

173. Nazik H, **Moss R,** Karna V, Clemons K, Banaei N, Cohen K, Choudhary V, Stevens DA. Are cystic fibrosis Aspergillus fumigatus isolates different? *Mycopathologica* 182:315-8, 2017.

174. Konstan MW, McKone EF, **Moss RB**, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS. Evidence for reduced rate of lung function decline and sustained benefit with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the *F508del-CFTR* mutation. *Lancet Resp Med* 5:107-18, 2017.

175. Char JE, Dunn C, Davies Z, Milla C, **Moss RB**, Wine JJ. The magnituge of ivacaftor effects on fluid secretion via R117H-CFTR channels: human *in vivo* measurements. *PLoS One* 12: e0175486, 2017.

176. Sabino R, Carolino E, **Moss RB**, Banaei N, Verissimo C, Stevens DA. Susceptibility of *Candida albicans* from cystic fibrosis patients. *Mycopathologia* 182:863-867, 2017.

177. Anand R, **Moss RB**, Sass G, Banaei N, Clemons DV, Martinez M, Stevens DA. Small colony variants of *Pseduomonas aeruginosa* display heterogeneity in inhibiting *Aspergillus fumigatus* biofilm. *Mycopathologia* 183:263-272, 2018.

178. Wagener JS, Millar SJ, Mayer-Hamblett N, Sawicki GS, McKone EF, Goss CH, Konstan MW, Morgan WJ, Pasta DJ, **Moss RB**. Lung function decline is delayed but not decreased in patients with cystic fibrosis and the *R117H* gene mutation. *J Cyst Fibros* 17:503-510, 2018.

179. Burgener E, **Moss RB**. CFTR modulators: precision medicine in Cystic Fibrosis. *Curr Opin Pediatr* 30:372-377, 2018.

180. Tracy MC, **Moss RB**. The myriad challenges of respiratory fungal infection in cystic fibrosis. *Pediatr Pulmonol* 53: S75-S85, 2018

181. Kim J, Farahmand M, Dunn C, Milla CE, Horii RI, Thomas EAC, **Moss RB**, Wine JJ. Sweat rate analysis of ivacaftor potentiation of CFTR in healthy humans: *Sci Rep* ;8:16233, 2018.

182. Forrest OA, Chopyk D, Gernez Y, Brown MR, Conrad CK, **Moss RB**, Tangpricha V, Peng L, Tirouvanziam R. Resistin is elevated in cystic fibrosis plasma and sputum and correlates negatively with lung function. *J Cyst Fibros* 18:64-70, 2019.

183. Robinson TE, Goris ML, **Moss RB**, Tian L, Kan P, Yilma M, McCoy KS, Newman B, de Jong PA, Long FR, Brody AS, Behrje R, Yates DP, Cornfield DN. Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease. *Pediatr Pulmonol* 55:929-938, 2020.

184. Nichols D, **Moss RB**. Early aspergillosis in cystic fibrosis and air trapping: guilt by association? *Am J Respir Crit Care Med* 201;644-645, 2020.

185. Chacko A, **Moss RB**. Manifestations of pulmonary aspergillosis in pediatrics. *Curr Opin Pediatr* 32:389-394, 2020.

186. **Moss RB**. Burned by the moral delusion: an illustration. *The Pharos* Autum 2020:46-48.

187. Pilewski J, De Boeck C, Nick J, Tian S, DeSouza C, Higgins M, **Moss RB**. Long-term ivacaftor in people aged 6 years and older with cystic fibrosis with ivacaftor-responsive mutations. *Pulm Ther* 6:303-313, 2020.

188. **Moss RB.** Mucosal humoral immunity in cystic fibrosis – a tangled web of failed proteostasis, infection and adaptive immunity. *EBioMedicine* 60:103035, 2020.

189. Li B, Huh SM, Prieto MD, Hong G, Schwarz C, **Moss RB**, Quon BS. Biomarkers for the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis: a systemic review and meta-analysis. *J Allergy Clin Immunol Pract* 9:1909-1930, 2021.

190. **Moss RB**. Diagnosing allergic bronchopulmonary aspergillosios/mycosis: Return to lost horizons. *J Alllergy Clin Immunol* 147:1212-1214, 2021.

191. Hong G, Desai S, **Moss RB**, Eschenhagen P, Quon BS, Schwarz C. Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: an international survey. J Cyst Fibros 21:136-142, 2022.

192. Sawicki GS, Konstan MW, McKone EF, **Moss RB**, Lubarksy B, Suthoff E, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan WJ, Duncan M, Yang Y. Rate of lung function decline in people with cystic fibrosis having a residual function gene mutation. Pulm Ther 8:385-395, 2022.

193. **Moss RB.** Severe fungal asthma: a role for biologics and inhaled antifungals. J Fungi (Basel) 9:85, 2023.

194. Levitt JE, Hedlin H, Duong S, Lu D, Lee J, Bunning B, Elkarra N, Pinsky BA, Heffernan E, Springman E, **Moss RB**, Bonilla HF, Parsonnet J, Zamanian RT, Langguth JJ, Bollyky J, Khosla C, Nicolls MR, Desai M, Rogers AJ. Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Clin Infect Dis 77:186-193, 2023.

195. Jjingo CJ, Bala S, Waack U, Needles M, Bensman TJ, McMaster O, Smith T, Blakely B, Chan IZ, Puthawala K, Dixon C, Kim Y, Lim R, Colangelo P, St Clair C, Nambiar S, **Moss RB**, Botgros R, Bazaz R, Denning DW, Marr KA, Husain S, Berman L, Christensen DJ, Keywood C, Clayton RG, Walsh TJ, Song HSE, Shukla SJ, Farley J. Food and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug Development. Clin Infect Dis 78:1564-1570, 2024.

196. **Moss RB.** T-cells and precision medicine for allergic bronchopulmonary aspergillosis. Eur Respir J 196. 63:2400549, 2024.

197. Agarwal R, Sehgal IS, Muthu V, Denning DW, Chakrabarti A, Soundappan K, Garg M, Rudramurthy SM, Dhooria S, Armstrong-James D, Asano K, Gangneux JP, Chotirmall SH, Salzer HJF, Chalmers JD, Godet C, Joest M, Page I, Nair P, Arjun P, Dhar R, Jat KR, Joe G, Krishnaswamy UM, Mathew JL, Maturu VN, Mohan A, Nath A, Patel D, Savio J, Saxena P, Soman R, Thangakunam B, Baxter CG, Bongomin F, Calhoun WJ, Cornely OA, Douglass JA, Kosmidis C, Meis JF, **Moss R**, Pasqualotto AC, Seidel D, Sprute R, Prasad KT, Aggarwal AN. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J 63:2400061, 2024.

198. Lewis T, Spano J, Kwok J, **Moss R**, Smith C, Mohabir PK, Sellers ZM, Cochrane-Snyman KC, Milla C. Peripheral muscle strength and lung function in adults with **cystic** fibrosis. Respir Med 252:108624, 2026.

BOOKS, CHAPTERS, INTERVIEWS

1. **Moss RB**. Immunology of cystic fibrosis: immunity, immunodeficiency, and hypersensitivity. In: Lloyd-Still JD (ed), *Textbook of Cystic Fibrosis*. Wright-PSG Publishing Inc., Boston, 1983, pp. 109-151.

2. **Moss RB**, Hsu YP, Leahy M, Halpern G. IgG_4 antibody to Pseudomonas aeruginosa in cystic fibrosis. In: Kerr JW, Ganderton MA (eds), *Proceedings of Invited Symposia, XII International Congress of Allergology and Clinical Immunology*, Macmillan, London, 1983, pp. 351-355.

3. Halpern GM, **Moss RB**, Hsu YP, Blessing J. Enzyme immunoassay for honeybee venom-specific IgG_4. In: Avrameas S (ed), *Immunoenzymatic Techniques*. Elsevier Science Publishers, Amsterdam, 1983, pp. 395-401.

4. Lewiston NJ, **Moss RB**. Allergic phenomena in cystic fibrosis. In: Shapira E, Wilson GB (eds), *Immunological Aspects of Cystic Fibrosis*. CRC Press Inc., Boca Raton, 1984, pp. 125-147.

5. **Moss RB**, Lewiston NJ. Immunopathology of cystic fibrosis. In: Shapira E, Wilson GB (eds), *Immunological Aspects of Cystic Fibrosis*. CRC Press Inc., Boca Raton, 1984, pp. 5-27.

6. Larrick JW, Dyer BJ, Senyk G, Hart SM, **Moss RB**, Lippman D, Jahnsen MC, Wang J, Weintraub H, Raubitschek AA. In vitro expansion of human B cells for the production of human monoclonal antibodies. In: Engleman EG, Foung SKH, Larrick JW, Raubitschek AA (eds), *Human Hybridomas and Monoclonal Antibodies*. Plenum Press, NY, 1985, pp. 149-165.

7. Larrick JW, Hart SM, Lippman D, Glembourtt M, Hsu YP, **Moss RB**. Generation and characterization of human monoclonal anti-Pseudomonas aeruginosa antibodies. In Strelkauskas A (ed), *Human Hybridomas: Diagnostic and Therapeutic Applications*. Marcel Dekker, Inc., New York, 1986, ch. 5, pp. 65-80.

8. **Moss RB**. IgG subclasses in respiratory disorders: cystic fibrosis. In: Shakib F (ed), *Basic and Clinical Aspects of IgG Subclasses. Monographs in Allergy, vol. 19*. SW Karger, Basel, 1986, pp. 202-209.

9. **Moss RB**, Editor. *Cystic Fibrosis*. *Infection, Immunopathology, and Host Response.* The Humana Press Inc., Totowa NJ, 1990, pp. 1-251.

10. **Moss RB**. Drug allergy in cystic fibrosis. In: Moss RB (ed). *Cystic Fibrosis*. *Infection, Immunopathology, and Host Response.* Humana Press, Clifton NJ, 1990, pp. 211-229.

11. **Moss RB**. Pediatric Respiratory Medicine: Gastroesophageal reflux-associated lung disease. In: Prober CG, Behrman RE (eds). *Nelson Self-Assessment in Pediatrics*, CME Supplement Test No. ZN9212, December 1992.

12. **Moss RB**. Pulmonary defenses. In: Hillman B (ed). *Pediatric Respiratory Diseases: Diagnosis and Treatment.* W.B. Saunders, Philadelphia, 1993, pp. 36-46.

13. **Moss RB**. Immunopathogenesis of cystic fibrosis lung disease. In: Hillman B (ed). *Pediatric Respiratory Diseases: Diagnosis and Treatment.* W.B. Saunders, Philadelphia, 1993, pp. 674-687.

14. **Moss RB**. Sinusitis and polyposis in cystic fibrosis. In: Druce HM, Ed. *Sinusitis--Pathophysiology and Treatment*. Marcel Dekker, New York, 1993, pp. 247-281.

15. **Moss RB**. Differential diagnosis of asthma in children. In: Gershwin ME and Halpern GM, Eds. *Bronchial Asthma. Principles of Diagnosis and Treatment,* 3rd Ed, The Humana Press Inc., Totowa NJ, 1994, pp. 141-169.

16. Light M, **Moss RB**, Davidson TM. Sinus disease in cystic fibrosis. In: Gershwin EM, & Incaudo GA, Eds. *Diseases of the Sinuses: A Comprehensive Textbook of Diagnosis and Treatment.* Humana Press, Inc., Totowa NJ, 1995, pp. 357-365.

17. HMS Beagle. Intrerviews with Scientists. *HMS Beagle* vol 63, 1 Oct 1999. http://www.bioscience.heacademy.ac.uk/ftp/employability/hmsbeagleinterviews.pdf

18. Schidlow D, Butler S, Eigen H, Johnson C, Konstan M, Marshall B, McColley S, Morgan W, **Moss R**, Rosenstein, B, Smaldone GC, Watrous M, Wagener J. *Cystic Fibrosis: From Theory to Practice.* Gardiner-Caldwell, SynerMed, MCP Hahnemann University, 2000.

19. **Moss RB**. Cystic fibrosis: new insights and treatments. *Hospital Practice* 36:25-37, 2001. Online at http://www.hosppract.com/issues/2001/01/moss.htm

20. **Moss RB** and Stevens DA. Cystic Fibrosis Foundation Consensus Conference recommendations on diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis: executive summary. CFF Consensus Conferences vol X, sect 3, Feb 2003.

21. Carter BJ, Munson K, Burstein H, Peluso R, Gerard C, Guggino W, Engelhardt J, Flotte T, **Moss R**. AAV-CFTR gene therapy for cystic fibrosis: retrospect and prospect. *Pediatric Pulmonology* Suppl 25, 159-160, 2003.

22. **Moss RB**. Inhalational antibiotics for airways infection. *Experimental Lung Research* 30: Suppl 1, 58-61, 2004.

23. Bloch EA, Germana J, Konstan M, Kuhn R, Llewellyn A, **Moss R**, Nickerson B, Rinker K, Sufian BS, VanDevanter D, Wagener J. Cystic Fibrosis: Treatment Practice Guidelines Pocket Guide. Professional Resources in Management Education, Inc., 2004.

24. **Moss RB**. Fungal Allergy in Cystic Fibrosis. In Kurup VS, Ed. *Mold Allergy, Biology and Pathogenesis 2005*, Research Signpost, Trivandrum, Kerala India, 2005, pp. 93-104.

25. Kurup VP, Knutsen AP, **Moss RB.** *Aspergillus* Antigens and Immunodiagnosis of Allergic Bronchopulmonary Aspergillosis. In Kurup VS, Ed. *Mold Allergy, Biology and Pathogenesis 2005*, Research Signpost, Trivandrum, Kerala India, 2005, pp. 137-146.

26. **Moss RB**. Gene therapy for cystic fibrosis: the rise and fall of a viral vector. *US RespiratoryDisease 2006*, 40-41.

27. **Moss RB.** Clinical management and monitoring lung function. In: Aggressive Treatment Strategies in the Fight Against Cystic Fibrosis (with JP Clancy). *Johns Hopkins Advanced Studies in Medicine* 7:440-450, 2007.

28. **Moss RB**. Fungal infection in chronic airway infection. *Commentaries on Chronic Airway Infection* vol 2, no 1, pp. 2-8, 2008.

29. **Moss RB**. Allergic bronchopulmonary aspergillosis. In Taussig LM, Landau LI, LeSouef PN, Martinez FD, Morgan WJ, Sly PD , Eds. *Pediatric Respiratory Medicine*, 2nd Ed, Elsevier, Inc., Toronto, Chpt 46, pp. 681-691, 2008.

30. **Moss RB.** Management of allergic aspergillosis. *Current Fungal Infection Reports* 2:87-93, 2008. Also published in: *Current Allergy and Asthma Reports* 8:433-9, 2008.

31. Robinson T, **Moss R**. Chest imaging in cystic fibrosis. *Commentaries on Chronic Airway Infection* vol 2, no 3, pp. 2-8, 2008.

32. **Moss RB.** Allergic bronchopulmonary aspergillosis. In: Latge JP, Steinbach WJ, Eds. *Aspergillus fumigatus and Aspergillosis.* American Society of Microbiology Press, Washington DC, Chpt 26, pp. 333-350, 2009.

33. **Moss RB**. Practicalities of ABPA diagnosis and treatment. *Pediatr Pulmonol* 44: Suppl 32, pp. 201-202, 2009.

34. **Moss RB**. Cystic fibrosis: pathophysiology and therapeutic Targets. In: Ahead of the Curve – Emerging CF Therapies. *Johns Hopkins Advanced Studies in Medicine* 10:9-13, 2010.

35. **Moss RB.** Allergic bronchopulmonary aspergillosis. *eCystic Fibrosis Review.* Jan 2010, http://www.eCysticFibrosisReview.org.

36. **Moss RB**. Allergic bronchopulmonary aspergillosis and *Aspergillus* infection in cystic fibrosis. *Curr Opinion Pulm Med* 16:598-603, 2010.

37. **Moss RB.** Lessons learned from the denufosol trials. *Pediatr Pulmonol* Suppl 34:177-8, 2011.

38. **Moss RB**. Epidemiology of fungal disease in cystic fibrosis. *Pediatr Pulmonol* Suppl 47:157-8, 2017.

39. **Moss RB.** Ho can COVID-19 transmission be prevented and treated? In: Sher Y, Stern TA, Fishman JA, Eds. *Facing the COVID-19 Pandemic and Its Aftermath: A Guide for Patients and their Families*. MGH Psychiatry Academy, Chapter 9:77-100, 2021.